

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Features and Trends of Thyroid Cancer in Patients with Thyroidectomies in Beijing, China between 1994 and 2015

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023334
Article Type:	Research
Date Submitted by the Author:	07-Apr-2018
Complete List of Authors:	Zhao, Ling; PLA General Hospital, Endocrinology and Metabolism Pang, Ping; Hainan Branch of PLA General Hospital, Endocrinology Zang , Li; PLA General Hospital, Endocrinology and Metabolism Luo, Yukun; PLA General Hospital, Ultrasonography Wang, Fulin; PLA General Hospital, Pathology Yang, Guoqing; PLA General Hospital, Endocrinology and Metabolism Du, Jin; PLA General Hospital, Endocrinology and Metabolism Wang, Xianling; PLA General Hospital, Endocrinology and Metabolism Lü, Zhaohui; Department of Endocrinology, Chinese People's Liberation Army General Hospital Dou , Jingtao; PLA General Hospital, Endocrinology and Metabolism Yiming, Mu; Chinese People's Liberation Army (PLA) General Hospital , Endocrinology and Metabolism
Keywords:	Thyroid cancer, Papillary thyroid carcinoma, microPTC

SCHOLARONE™  
Manuscripts

Only

1  
2  
3 **Features and Trends of Thyroid Cancer in Patients with Thyroidectomies in Beijing,**  
4 **China between 1994 and 2015**  
5  
6

7 **Running Title:** Evolution of thyroid cancer in China  
8  
9

10  
11 Ling Zhao <sup>1#</sup>, Ping Pang <sup>2#</sup>, Li Zang <sup>1</sup>, Yukun Luo <sup>3</sup>, Fulin Wang <sup>4</sup>, Guoqing Yang <sup>1</sup>, Jin Du<sup>1</sup>,  
12 Xianling Wang <sup>1</sup>, Zhaohui Lyu <sup>1\*</sup>, Jingtao Dou <sup>1</sup>, Yiming Mu <sup>1</sup>  
13  
14

15  
16 <sup>1</sup> The Department and Key Laboratory of Endocrinology and Metabolism, PLA General  
17 Hospital, Beijing, 100853, China;

18  
19 <sup>2</sup> Department of Endocrinology, Hainan Branch of PLA General Hospital, Sanya, 572013,  
20 Hainan, China;

21  
22 <sup>3</sup> Department of Ultrasonography, PLA General Hospital, Beijing, 100853, China;

23  
24 <sup>4</sup> Department of Pathology, PLA General Hospital, Beijing, 100853, China.  
25  
26

27 **\*Corresponding author:**

28 Zhao-hui Lyu, MD

29 Department of Endocrinology, PLA General Hospital, No. 28, Fuxing Road, Haidian District,  
30 Beijing, 100853, China  
31

32 Tel: +86 186 1011 1788, Email: [metabolism301@126.com](mailto:metabolism301@126.com)  
33  
34  
35

36  
37 <sup>#</sup> These authors contributed equally to the study  
38  
39

40 **Keyword:** Thyroid cancer; Papillary thyroid carcinoma; microPTC  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Objectives:** This study aims to summarize the features and trends of thyroid carcinoma in the past two decades in China.

**Design, Setting and Participants:** Clinical data obtained from 10,798 patients treated by thyroidectomy from 1994 to 2015 at the Department of General Surgery of the People's Liberation Army General Hospital, Beijing, China were retrospectively analyzed.

**Outcome measures:** Incidence and histopathological features of thyroid cancer were compared and the risk factors for local lymph node metastasis analyzed.

**Results:** Our data indicated a significant increase in the detection of thyroid cancer (from 16.8% to 69.8%,  $P < 0.01$ ). Among the 5,235 thyroid cancer cases, papillary thyroid carcinoma (PTC) was the most common histotype, accounting for 95.1% of all malignancies over the 22-year period. Among the 4,979 PTCs, microPTCs (mPTC) with the largest diameter  $\leq 10$  mm has gradually become the dominant form, and the percentage of it in PTCs has increased from 13.3% in the biennial period of 1994-1995 to 51.2% in 2010-2011. Furthermore, the size of the tumor has decreased significantly from  $2.3 \pm 1.1$  cm in 1994 to  $1.2 \pm 0.9$  cm in the largest diameter ( $P < 0.01$ ), while the average age at diagnosis and female dominance remained unchanged during the period. Logistic regression showed that tumor nodules  $> 1$  cm and male gender are the main risk factors for local lymph node metastasis (LNM) whereas patients over 45 years had lower risk.

**Conclusions:** During the 22-year period, an increased detection of thyroid cancer, particularly mPTC, was found while occurrence of LNM decreased. Our results suggest that the current preoperative diagnosis and risk stratification are adequate, supporting the published guidelines for the diagnosis of thyroid cancer.

## Strengths and limitations of this study

- The retrospective study analyzed the clinicopathological data of thyroid cancer over a period of 22 years
- The study identified major risk factors for the lymph node metastasis of thyroid cancer
- The retrospective nature of this study led to limited survival data which should have been included to evaluate the improvement of clinical outcome during the 22-year period.

## Introduction

Thyroid nodules occur in about 4-7% of the population and 8-16% of them contain malignant elements<sup>1</sup>. Thyroid cancer is the most common endocrine cancer<sup>1</sup>, and approximately 90% of them are differentiated, including predominantly papillary thyroid carcinoma (PTC) and, to a less extent, follicular thyroid carcinoma<sup>2</sup>. These subtypes are generally associated with a more favorable prognosis and higher cure rate<sup>3</sup>, compared with less common but more aggressive forms of thyroid cancer, such as medullary thyroid cancer, anaplastic thyroid cancer, and thyroid sarcoma or lymphoma<sup>4</sup>.

The past few decades have witnessed an increase in the incidence of thyroid cancer while the associated mortality remains unchanged<sup>5-9</sup>. Also increased is the number of cases of newly diagnosed thyroid cancer with smaller tumors. Between 2008 and 2009, 39% of thyroid cancer patients were diagnosed with tumors smaller than 1 cm, compared to 25% between 1988 and 1989<sup>10</sup>. This is due to the proactive screening of thyroid cancer, particularly by the application of sensitive surveillance modality in recent years<sup>11-15</sup>. Advanced imaging techniques, such as ultrasonography, computational tomography, magnetic resonance imaging, and positron emission tomography, along with fine-needle aspiration biopsy, have dramatically improved the detection of small thyroid nodules and facilitated the early diagnosis of thyroid cancer<sup>16-18</sup>.

However, the increased incidence of thyroid cancer is also believed to be associated with over-diagnosis<sup>18-22</sup> and environmental factors<sup>6,23</sup>. The screening of highly prevalent thyroid nodules for those with malignant potential remains to be challenging although a number of guidelines have recently been proposed for the diagnosis and management of thyroid nodules<sup>24</sup>. Identifying nodules with high risk of malignancy during thyroidectomy represents a cost-effective approach<sup>25,26</sup>. Therefore in this study the features and trends of thyroid cancer in patients with thyroidectomies in China were retrospectively analysed to examine whether the decrease in the diagnosable size of thyroid nodules is associated with misdiagnosis, and provide further insight into its diagnosis and management.

## Materials and methods

This study was approved by the Chinese People's Liberation Army (PLA) General Hospital Ethics Committee and written informed consents obtained from all patients for retrospective studies.

## Data collection

1  
2  
3 Clinical database for patients undergoing thyroidectomies from 1994 to 2015 at the  
4 Department of General Surgery of PLA General Hospital (Beijing, China) was revisited, and  
5 the reported thyroid pathology screened and reviewed to analyse the correlation of the size of  
6 thyroid nodules with other pathological features.  
7  
8

9 Clinical parameters used in the analysis included front neck discomfort or pain,  
10 dysphagia, dysphonia or hoarseness, dyspnea, sign of thyroid nodule and thyroid gland  
11 enlargement, as well as ultrasound features. Data were individually checked and cases with  
12 inconsistent data were excluded before statistical analysis. As a result, 10,798 eligible cases  
13 with thyroidectomies from 1994 to 2015 were recruited.  
14  
15  
16  
17  
18

### 19 ***Data analysis and statistics***

20 Benign or malignant thyroid nodules were diagnosed based on pathological features, and  
21 malignant nodules were reported as papillary (PTC), follicular (FTC), medullary (MTC), or  
22 anaplastic thyroid carcinoma (ATC). Papillary thyroid carcinomas were further sub-classified  
23 into clinically relevant PTCs (crPTCs) > 10 mm in diameter and micro-PTCs (mPTCs) ≤ 10  
24 mm in diameter (the largest diameter of a nodule). These sub-groups were compared, when  
25 appropriate, in the analysis.  
26  
27  
28  
29

30 Statistical analysis was performed using the Statistical Package for the Social Sciences  
31 (SPSS, Version 17.0, IBM, Armonk, NY). Data are shown as mean±standard deviation or  
32 mean±standard error, when appropriate. Chi-square test was used to compare different  
33 categories and generate the trend lines, *t*-test employed to compare between groups, and  
34 logistic regression performed to calculate the risk factors for lymph node metastasis (LNM).  
35 Data analysis was adjusted for confounders such as age, gender, nodule size, and the presence  
36 of Hashimoto thyroiditis, and two-tailed  $P < 0.05$  was considered statistically significant.  
37  
38  
39  
40  
41  
42

### 43 ***Patient and public involvement***

44 This is a retrospective study, with no involvement of patients or publics in the  
45 development of research initiative and outcome measures and the design and implementation  
46 of the study. It covers a period of 22 years between 1994 and 2015; therefore, there is no  
47 possibility or plan to disseminate the results among the participants.  
48  
49  
50  
51  
52

## 53 **Results**

### 54 ***Maligancy rate increased from 1994 to 2015.***

55 The numbers of benign and malignant cases of thyroid cancer detected during  
56  
57  
58  
59  
60

1  
2  
3 thyroidectomy from 1994 to 2015 are summarized in table 1. With an increase in the number  
4 of thyroidectomy surgeries, as a result of improved diagnosis of thyroid cancer, the numbers  
5 of benign and malignant cases increased gradually. Noticeably, the malignancy rate of thyroid  
6 nodules increased dramatically from 16.8% during the biennial period of 1994-1995 to 69.8%  
7 during 2014-2015 ( $P<0.05$ ), whereas the benign rate decreased from 83.2% to 30.2%  
8 ( $P<0.05$ ).  
9  
10  
11  
12

#### 13 14 ***Diagnosis rate of PTC increased from 1994 to 2015.***

15  
16 Among the 10,798 cases recruited, 5,235 cases were found to be malignant (Table 2). A  
17 majority of patients (63.6%) were found with multiple cancers. Moreover, 48.1% of the  
18 patients had unilateral cancer and the remaining 51.9% had bilateral cancer (Table 2). In  
19 addition, most of the malignant cases were recorded as PTCs, which exhibited a significant  
20 increase from 65.3% during period of 1994-1995 to 98.2% during 2014-2015 ( $P<0.05$ ,  
21 Figure 1), while the diagnosis rates of other histotypes decreased concurrently (Table 2 and  
22 Figure 1).  
23  
24  
25  
26  
27  
28

#### 29 ***Detection size of thyroid nodules decreased from 1994 to 2015.***

30  
31 Reviewing the clinicopathological information of malignant cases suggested that most of  
32 the patients were free of clinically relevant symptoms and physical signs (Figure 2A, 2B),  
33 with only 9% showing different degrees of discomfort, such as pain and dysphagia.  
34 Enlargement of thyroid glands were often noticed, unnecessarily by health professionals,  
35 during routine physical examination; however, 34% of tumors were impalpable likely due to  
36 the depth of intra-thyroidal microcarcinoma. By ultrasonography, 37% of patients were  
37 detected with single thyroid tumors, while the others had multiple lesions (Figure 2C).  
38  
39  
40  
41

42 From 1994 to 2015, the size of thyroid nodules reported decreased significantly, with the  
43 mean diameter reduced from  $2.6\pm 1.4$  cm to  $1.2\pm 0.9$  cm (Figure 2D). This trend roughly  
44 correlated with an increase in the rate of preoperative fine needle aspiration (FNA), from  
45 15% in 2004 to 74% in 2013, although this rate regressed to 57% between 2014 and 2015  
46 (Figure 2E). Also of relevance, during the same period, the total thyroidectomy rate remained  
47 unchanged from 1994 to 2007, but gradually increased from 2008 to 2013, and decreased  
48 sharply to 3% from 2014 to 2015 (Figure 2F).  
49  
50  
51  
52  
53  
54

#### 55 ***Size of thyroid cancer at diagnosis and metastasis rate decreased from 1994 to 2015***

56 Considering the high prevalence of PTCs, 4,980 cases compared to 255 cases of other  
57  
58  
59  
60

subtypes all-together, further data analysis was restricted to this type of thyroid cancer. As shown in Table 3, the mean age of patients at diagnosis was  $43.7 \pm 11.3$  years old, with no significant variation from 1994 to 2015. Incidence of PTC in women was considerably higher than in men, with approximately two thirds of these patients were female. Of note, the average diameter of PTCs at diagnosis decreased from  $2.3 \pm 1.1$  cm in 1994 to  $1.2 \pm 0.9$  cm in 2015 ( $P < 0.05$ , Table 3). Correlating with this trend was the increase in the percentage of mPTCs from 13.3% between 1994 - 1995 to 51.2% during 2010 – 2011 ( $P < 0.05$ , Table 3). Interestingly, the detection rate of mPTCs decreased to 26.5 between 2014 and 2015.

Analysis of the incidence of LNM of thyroid cancer in parallel among 4,980 cases of PTCs demonstrated a significant reduction in the occurrence of LNM with a decrease of tumor size ( $P < 0.05$ , Table 3). This is associated with the increased diagnosis rate of mPTCs, which shows an apparently lower LNM potential in comparison with crPTCs (Table 4). Before 2007, the difference between the LNM rates of mPTC and crPTC were appreciable but most of time not statistically significant due to the limited cohort sizes. With the increase of PTC diagnosis after 2008, a significantly lower LNM occurrence was found for mPTCs, compared to crPTCs (Table 4).

### ***Determinant factors of local lymph node metastasis in PTC, mPTC and crPTC***

To identify the risk factors for local LNM in PTC, mPTC, and crPTC, logistic regression was performed. The results support a correlation of LNM with nodules  $> 1$  cm [odds ratio (OR): 2.480, confidence interval (CI): 0.428 – 0.613,  $P < 0.001$ ] and male gender (OR: 1.627, CI: 1.376 – 1.923,  $P < 0.001$ ) as well as an inverse correlation with  $\geq 45$  years (OR: 0.512, CI: 2.040 – 2.902,  $P < 0.001$ ) after adjustment for other covariates in all PTCs (Figure 3A, Table 2). Hashimoto's thyroiditis presented no risk for LNM (Figure 3A). Consistent data were also obtained in patients with mPTC and crPTC (Figure 3B & 3C, Table 3 and Table 4).

### **Discussion**

Thyroid cancer is diagnosed in nearly 65000 people annually all over the world<sup>25-27-29</sup>. Although these malignancies are mostly differentiated and generally associated with good prognosis, involvement of local lymph nodes is frequently observed. Proactive screening for malignancies from a substantial population of thyroid nodes and accurate histopathological stratification are crucial for the clinical decision and improvement of patient outcome. This study reviewed 10,798 cases of thyroidectomy undertaken in a major hospital in one of the most populated city in the world over a period of 22 years, summarized the clinical features



1  
2  
3 of 5,235 cases of thyroid cancer, and analysed the trend of PTCs and risk factors predicting  
4 LNM.  
5

6 Our analysis unveiled a gradual but significant increase of thyroid malignancy detection  
7 rate over the period from 1994 to 2015, from 16.8% to 69.8%. These percentages are  
8 generally within the wide-range of detection rate (6.7-56%) of thyroid cancer worldwide<sup>25 28</sup>  
9<sup>29</sup>, although data between 2014 and 2015 was relatively higher than earlier periods. Variations  
10 in the detection rates across different centers are likely caused by the different guidelines and  
11 algorithms followed by physicians and surgeons. The increase of detection rate from 1994 to  
12 2015 reflects an improvement in the diagnosis, through the advances in imaging technologies  
13 and the increasing use of FNA. In addition, appropriate preoperative risk stratification of  
14 thyroid nodules, as a result of improved clinical evaluation, thyroid function test,  
15 ultrasonography, and molecular diagnosis, in recent years diverts a lot of patients from  
16 thyroidectomy, contributing to the increased diagnosis of thyroid cancer. These data support  
17 the published guideline<sup>30 31</sup> and highlight the importance of combining imaging, FNA,  
18 cytology, and molecular diagnosis. However, we can't rule out the contribution of social and  
19 environmental stresses, which is beyond the scope of this retrospective study. It is noteworthy  
20 that this study covered a period during which China was undergoing the largest scale of  
21 industrialisation in modern history that inevitably led to dramatic social and environmental  
22 changes.  
23

24 Papillary carcinoma accounts for 95.1% of malignancies in the whole cohort, and as high  
25 as 98.2% among patients diagnosed between 2014 and 2015. These rates are comparable to  
26 the findings of another study performed in Nanjing, China<sup>25</sup>, but higher than other reports<sup>32</sup>,  
27 likely due to the increase of PTCs, as previously suggested<sup>33</sup>. The high detection rate for  
28 PTC is attributable to the increasing use of head and neck imaging, which detects  
29 sub-palpable (yet potentially malignant) thyroid nodules, and ultrasound-guided FNA, which  
30 improves the preoperative detection of malignancy. With the use of head and neck  
31 ultrasonography and other diagnostic approaches, the average size of PTC at diagnosis has  
32 significantly reduced from 2.3±1.1 cm in 1994 to 1.2±0.9 cm in 2015, similar to the trends  
33 reported in previous studies<sup>10 25</sup>. This progress allows early detection of thyroid cancer which  
34 leads to an increasing trend of hemithyroidectomy, compared to total thyroidectomy, and  
35 intensified follow-up of thyroid cancer patients in recent years in our practice following the  
36 American Thyroid Association (ATA) guidelines<sup>30 31 33</sup>. However, the overdiagnosis and  
37 overtreatment of indolent diseases have been increasingly recognized. The most recent ATA  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 guidelines suggest a more parsimonious evaluation of thyroid nodules and a more judicious  
4 use of thyroid cancer treatment to minimize risks and maximize benefits to patients<sup>33</sup>.  
5

6 Our data suggests that >1 cm nodules and the male gender predict a high risk of LNM  
7 while age  $\geq 45$  years is associated with low LNM potentials, consistent with previous finding  
8<sup>25</sup>. Therefore, more attention is needed for these patients in future practice. In this  
9  
10 single-center study, however, factors taken into account for logistic regression analysis were  
11 limited due to the retrospective nature of this study. Future studies are needed to characterise  
12 the association of other clinical and biochemical parameters with thyroid cancer metastasis  
13 and patient outcome. Characterising the contribution of social and environmental stresses to  
14 the occurrence of thyroid cancer will also be of significant social economical value.  
15  
16  
17  
18  
19

20  
21 In this study, we retrospectively analysed the clinical data of 10,798 patients treated by  
22 thyroidectomy to study the features and trends of thyroid cancer in the past 22 years. Our data  
23 suggest significant increase in the detection rate of thyroid cancer, in particular mPTC, which  
24 has become the dominant form of thyroid cancer. As a result, the occurrence of LNM has  
25 been decreasing with time. Our results suggest the adequacy of current preoperative diagnosis  
26 and risk stratification, although overdiagnosis and overtreatment require future attention of  
27 physicians and surgeons in view of the rapid increase in the number of thyroidectomies.  
28  
29  
30  
31  
32

### 33 **Acknowledgements**

34 We gratefully acknowledge the invaluable contribution of doctors and nurses from the  
35 Chinese PLA General Hospital and the patients involved in this study.  
36  
37  
38  
39

### 40 **Funding**

41 This study was supported by a grant from the Medical Science and Technology Foundation of  
42 the Military “Twelve-Five” Program (CWS11J063) to ZHL  
43  
44  
45

### 46 **Authors' contributions**

47 ZL designed the study, collected and analysed data, and wrote the manuscript. PP contributed  
48 to manuscript writing. ZL, LYK, WFL, YGQ, DJ, and WXL assisted with data presentation  
49 and manuscript writing. LZH, DJT and MYM contributed into study design, data analysis,  
50 and manuscript writing. All authors read and approved the final manuscript.  
51  
52  
53  
54  
55

### 56 **Competing interests**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

The authors have no conflicts of interest to disclose.

**Data sharing statement:** Data will be available upon request to the corresponding author

For peer review only

## References

1. Burman KD, Wartofsky L. CLINICAL PRACTICE. Thyroid Nodules. *N Engl J Med* 2015;373:2347-56.
2. Ron E, Schneider AB. Thyroid Cancer In: Schottenfeld D, Jr. FJF, eds. *Cancer Epidemiology and Prevention* New York: Oxford University Press, 2006:975-94.
3. Schlumberger MJ. Papillary and follicular thyroid carcinoma. *N Engl J Med* 1998;338:297-306.
4. Spielman DB, Badhey A, Kadakia S, et al. Rare Thyroid Malignancies: an Overview for the Oncologist. *Clin Oncol (R Coll Radiol)* 2017;29:298-306.
5. Brito JP, Kim HJ, Han SJ, et al. Geographic Distribution and Evolution of Thyroid Cancer Epidemic in South Korea. *Thyroid* 2016;26:864-5.
6. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. *Cancer Epidemiol Biomarkers Prev* 2009;18:784-91.
7. Pandeya N, McLeod DS, Balasubramaniam K, et al. Increasing thyroid cancer incidence in Queensland, Australia 1982-2008 - true increase or overdiagnosis? *Clin Endocrinol (Oxf)* 2015.
8. Uhry Z, Colonna M, Remontet L, et al. Estimating infra-national and national thyroid cancer incidence in France from cancer registries data and national hospital discharge database. *Eur J Epidemiol* 2007;22:607-14.
9. Wang Y, Wang W. Increasing incidence of thyroid cancer in Shanghai, China, 1983-2007. *Asia Pac J Public Health* 2015;27:NP223-9.
10. Davies L, Welch HG. Current thyroid cancer trends in the United States. *JAMA Otolaryngol Head Neck Surg* 2014;140:317-22.
11. Brito JP, Gionfriddo M, Morris JC, et al. Overdiagnosis of thyroid cancer and graves'

- 1  
2  
3 disease. *Thyroid* 2014;24:402-3.  
4  
5 12. Brito JP, Hay ID, Morris JC. Low risk papillary thyroid cancer. *BMJ* 2014;348:g3045.  
6  
7 13. Brito JP, Morris JC, Montori VM. Thyroid cancer: zealous imaging has increased  
8  
9 detection and treatment of low risk tumours. *BMJ* 2013;347:f4706.  
10  
11 14. Kilfoy BA, Zheng T, Holford TR, et al. International patterns and trends in thyroid cancer  
12  
13 incidence, 1973-2002. *Cancer Causes Control* 2009;20:525-31.  
14  
15 15. Trimboli P, Guglielmi R, Monti S, et al. Ultrasound sensitivity for thyroid malignancy is  
16  
17 increased by real-time elastography: a prospective multicenter study. *J Clin*  
18  
19 *Endocrinol Metab* 2012;97:4524-30.  
20  
21 16. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States,  
22  
23 1973-2002. *JAMA* 2006;295:2164-7.  
24  
25 17. Kent WD, Hall SF, Isotalo PA, et al. Increased incidence of differentiated thyroid  
26  
27 carcinoma and detection of subclinical disease. *CMAJ* 2007;177:1357-61.  
28  
29 18. Sosa JA, Hanna JW, Robinson KA, et al. Increases in thyroid nodule fine-needle  
30  
31 aspirations, operations, and diagnoses of thyroid cancer in the United States. *Surgery*  
32  
33 2013;154:1420-6; discussion 6-7.  
34  
35 19. Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic"--screening and  
36  
37 overdiagnosis. *N Engl J Med* 2014;371:1765-7.  
38  
39 20. Brito JP, Davies L. Is there really an increased incidence of thyroid cancer? *Curr Opin*  
40  
41 *Endocrinol Diabetes Obes* 2014;21:405-8.  
42  
43 21. Franceschi S, Vaccarella S. Thyroid cancer: an epidemic of disease or an epidemic of  
44  
45 diagnosis? *Int J Cancer* 2015;136:2738-9.  
46  
47 22. Morris LG, Tuttle RM, Davies L. Changing Trends in the Incidence of Thyroid Cancer in  
48  
49 the United States. *JAMA Otolaryngol Head Neck Surg* 2016;142:709-11.  
50  
51 23. Aschebrook-Kilfoy B, Grogan RH. Re: Brito et al., overdiagnosis of thyroid cancer and  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 Graves' disease. *Thyroid* 2014;24:403-4.  
4  
5 24. Paschke R, Hegedus L, Alexander E, et al. Thyroid nodule guidelines: agreement,  
6  
7 disagreement and need for future research. *Nat Rev Endocrinol* 2011;7:354-61.  
8  
9 25. Liu X, Zhu L, Wang Z, et al. Evolutionary features of thyroid cancer in patients with  
10  
11 thyroidectomies from 2008 to 2013 in China. *Sci Rep* 2016;6:28414.  
12  
13 26. Liu XY, Zhu LJ, Cui D, et al. Annual financial impact of thyroidectomies for nodular  
14  
15 thyroid disease in China. *Asian Pac J Cancer Prev* 2014;15:5921-6.  
16  
17 27. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016;66:7-30.  
18  
19 28. Wienhold R, Scholz M, Adler JR, et al. The management of thyroid nodules: a  
20  
21 retrospective analysis of health insurance data. *Dtsch Arztebl Int* 2013;110:827-34.  
22  
23 29. Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary  
24  
25 approach to thyroid nodule diagnostic evaluation. *Cancer* 2007;111:508-16.  
26  
27 30. American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated  
28  
29 Thyroid C, Cooper DS, et al. Revised American Thyroid Association management  
30  
31 guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid*  
32  
33 2009;19:1167-214.  
34  
35 31. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with  
36  
37 thyroid nodules and differentiated thyroid cancer. *Thyroid* 2006;16:109-42.  
38  
39 32. Othman NH, Omar E, Naing NN. Spectrum of thyroid lesions in hospital Universiti Sains  
40  
41 Malaysia over 11years and a review of thyroid cancers in Malaysia. *Asian Pac J*  
42  
43 *Cancer Prev* 2009;10:87-90.  
44  
45 33. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association  
46  
47 Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated  
48  
49 Thyroid Cancer: The American Thyroid Association Guidelines Task Force on  
50  
51 Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* 2016;26:1-133.  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1. Detection rate of malignancy among patients undergoing thyroidectomy from 1994 to 2015**

Period	94.1-95.12	96.1-97.12	98.1-99.12	00.1-01.12	02.1-03.12	04.1-05.12	06.1-07.12	08.1-09.12	10.1-11.12	12.1-13.12	14.1-15.12	Total	<i>P</i>
Benign, <i>n</i>	114	136	169	268	286	495	535	738	901	1033	890	5563	<0.001
(%)	(83.2)	(86.1) <sup>a,b</sup>	(88.0) <sup>a,b</sup>	(83.0) <sup>a</sup>	(80.1) <sup>a,b</sup>	(79.2) <sup>b</sup>	(71.4) <sup>a,b</sup>	(64.6) <sup>a,b</sup>	(52.4) <sup>a,b</sup>	(42.2) <sup>a,b</sup>	(30.2) <sup>a,b</sup>	(51.5)	
Cancer, <i>n</i>	23	22	23	55	71	130	214	405	817	1413	2060	5235	
(%)	(16.8)	(13.9) <sup>a,b</sup>	(12.0) <sup>a,b</sup>	(17.0) <sup>a</sup>	(19.9) <sup>a,b</sup>	(20.8) <sup>b</sup>	(28.6) <sup>a,b</sup>	(35.4) <sup>a,b</sup>	(47.6) <sup>a,b</sup>	(57.8) <sup>a,b</sup>	(69.8) <sup>a,b</sup>	(48.5)	
Total	137	158	192	323	357	625	749	1143	1718	2446	2950	10798	

<sup>a</sup> Percentages significantly different from the previous year; <sup>b</sup> Percentages significantly different from period 94.1-95.12.

**Table 2. Pathological classification of all thyroid malignancies from 1994 to 2015**

Period	94.1- 95.12	96.01- 97.12	98.1- 99.12	00.1- 01.12	02.1- 03.12	04.1- 05.12	06.1- 07.12	08.1- 09.12	10.1- 11.12	12.1- 13.12	14.1- 15.12	<i>P</i> for difference	<i>P</i> for trend
PTC, <i>n</i> (%)	15 (65.3)	17 (77.3)	17 (73.9)	39 (70.9)	50 (70.4)	107 (82.3)	185 (86.4)	383 (94.6)	768 (94.0)	1376 (97.4)	2023 (98.2)	<0.001	<0.001
FTC, <i>n</i> (%)	3 (13.0)	1 (4.5)	4 (17.3)	10 (18.1)	9 (12.7)	17 (13.1)	18 (8.4)	9 (2.2)	25 (3.0)	17 (1.2)	20 (0.9)	<0.001	<0.001
MTC, <i>n</i> (%)	1 (4.3)	2 (9.1)	1 (4.3)	4 (7.3)	2 (2.8)	1 (0.8)	2 (0.9)	5 (1.2)	14 (1.7)	12 (0.8)	12 (0.6)	<0.001	<0.001
ATC, <i>n</i> (%)	0 (0)	0 (0)	1 (4.3)	1 (1.8)	3 (4.2)	1 (0.8)	1 (0.5)	2 (0.5)	1 (0.1)	1 (0.1)	2 (0.1)	<0.001	<0.001
Other, <i>n</i> (%)	4 (17.4)	2 (9.1)	0 (0)	1 (1.8)	7 (9.9)	4 (3.1)	7 (3.3)	6 (1.5)	9 (1.1)	7 (0.5)	3 (0.1)	<0.001	<0.001
Unilateral	14 (60.9)	14 (63.6)	13 (56.5)	31 (56.4)	38 (53.5)	72 (55.4)	122 (57.0)	213 (52.6)	389 (47.6)	616 (43.6)	991 (48.1)	0.071	<0.001
Bilateral	9 (39.1)	8 (36.4)	10 (43.5)	24 (43.6)	33 (46.5)	58 (44.6)	92 (43.0)	192 (47.4)	428 (52.4)	797 (56.4)	1069 (51.9)		
Solitary	7 (30.4)	13 (59.1)	11 (47.8)	27 (49.1)	28 (39.4)	59 (45.4)	105 (49.0)	172 (42.5)	292 (35.7)	456 (32.3)	749 (36.4)	<0.001	<0.001
Multiple	16 (69.6)	9 (40.9)	12 (52.2)	28 (50.9)	43 (60.6)	71 (54.6)	109 (51.0)	233 (57.5)	525 (64.3)	957 (67.7)	1311 (63.6)		
All cancer, <i>n</i>	23	22	23	55	71	130	214	405	817	1413	2060		

PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; MTC, medullary thyroid carcinoma; ATC, anaplastic thyroid carcinoma; other histotypes of carcinoma collectively refer to cancer other than PTC, FTC, MTC, and ATC, including poorly differentiated thyroid cancer, squamous cell carcinomas, B cell lymphomas of thyroid, spindle cell carcinoma, adenoid cystic carcinoma, renal clear cell metastasis and Langerhans cell histiocytosis of the thyroid gland.



**Table 3. Clinicopathological feature of PTCs from 1994 to 2015**

Period	94.1- 95.12	96.1- 97.12	98.1- 99.12	00.1- 01.12	02.1- 03.12	04.1- 05.12	06.1- 07.12	08.1- 09.12	10.1- 11.12	12.1- 13.12	14.1- 15.12	Total	<i>P</i> for difference	<i>P</i> for trend
Age, year	46.9±14.3	43.1±10.7	41.1±12.9	44.9±14.8	44.6±14.5	43.8±12.4	44.6±12.4	42.7±12.4	43.9±11.2	43.9±11.1	43.6±10.9	43.7±11.3	0.643	
Male, <i>n</i>	5	3	6	11	18	34	60	115	227	366	616	1461	0.434	0.664
(%)	(33.3)	(17.6)	(35.3)	(28.2)	(36)	(31.8)	(32.4)	(30.0)	(29.6)	(26.6)	(30.4)	(29.3)		
Female, <i>n</i>	10	14	11	28	32	73	125	268	541	1010	1407	3519		
(%)	(66.7)	(82.4) <sup>ab</sup>	(64.7.0) <sup>a</sup>	(71.8) <sup>a</sup>	(64) <sup>a,b</sup>	(68.2) <sup>b</sup>	(67.6) <sup>a,b</sup>	(70.0) <sup>a,b</sup>	(70.4) <sup>a,b</sup>	(73.4) <sup>a</sup>	(69.6) <sup>a</sup>	(70.7)		
Size <sup>c</sup> , cm	2.3±1.1	2.6±1.9	2.1±1.3	2.2±1.6	2.2±1.4	2.2±1.6	1.7±1.1 <sup>ab</sup>	1.5±1.0 <sup>b</sup>	1.3±0.9 <sup>ab</sup>	1.2±0.8 <sup>ab</sup>	1.2±0.9 <sup>b</sup>	1.4±1.0	<0.001	
CrPTC, <i>n</i>	13	15	12	32	41	87	118	238	375	696	1486	3113	<0.001	0.213
(%)	(86.7)	(88.2)	(70.6)	(82.1)	(82.0)	(81.3)	(63.8) <sup>a</sup>	(62.1) <sup>b</sup>	(48.8) <sup>ab</sup>	(50.6) <sup>b</sup>	(73.5) <sup>a</sup>	(62.5)		
mPTC, <i>n</i>	2	2	5	7	9	20	67	145	393	680	537	1866		
(%)	(13.3)	(11.8)	(29.4)	(17.9)	(18.0)	(18.7)	(36.2)	(37.9)	(51.2)	(49.4)	(26.5)	(37.5)		
LNM, <i>n</i>	5	5	7	22	17	27	55	96	192	372	414	1212	<0.001	<0.001
(%)	(33.3)	(29.4)	(41.2)	(56.4)	(34)	(25.2)	(29.7)	(25.1)	(25.0)	(27.0)	(20.5) <sup>a</sup>	(24.3)		
No-LNM, <i>n</i>	10	12	10	17	33	80	130	287	576	1004	1609	3768		
(%)	(66.7)	(70.6)	(58.8)	(43.6)	(66)	(74.8)	(70.3)	(74.9)	(75.0)	(73.0)	(79.5)	(75.7)		
Total	15	17	17	39	50	107	185	383	768	1376	2023		<0.001	<0.001

<sup>a</sup> Percentages significantly different from the previous year; <sup>b</sup> Percentages significantly different from period 08.1-09.12; <sup>c</sup> Mean diameter; crPTC, clinical relevant papillary thyroid carcinoma; mPTC, micro papillary thyroid carcinoma; LNM, lymph node metastasis; LN, lymph node.

**Table 4. Rate of local lymph node metastasis in patients with crPTC and mPTC from 2008 to 2013**

	94.1	96.1	98.1	00.1	02.1	04.1	06.1	08.1	10.1	12.1	14.1	Total	<i>P</i> for difference	<i>P</i> for trend
	-95.12	-97.12	-99.12	-01.12	-03.12	-05.12	-07.12	-09.12	-11.12	-13.12	-15.12			
crPTC, <i>n</i> (%)	3 (23.1)	5 (33.3)	6 (50.0)	19 (59.4)	17 (41.5)	24 (27.6)	35 (29.7)	73 (30.7)	130 (34.7)	243 (34.9)	330 (22.2)	885 (28.4)	<0.001	<0.001
mPTC, <i>n</i> (%)	2 (100)	0 (0)	1 (20.0)	3 (42.9)	0 (0)	3 (15.0)	20 (29.9)	23 (16.0)	62 (15.8)	129 (19.0)	84 (15.6)	327 (17.5)	0.005	0.087
<i>P</i> -value	0.032	0.331	0.252	0.425	0.017	0.243	0.978	0.001	0.000	0.000	0.001			

crPTC, clinical relevant papillary thyroid carcinoma; mPTC, micro papillary thyroid carcinoma.

### Figure legends

**Figure 1.** Trends in the diagnosis of various subtype thyroid malignancies from 1994 to 2015.

**Figure 2.** Clinical, surgical and ultrasound features during the evolvement of thyroidectomy and the diagnosis of thyroid cancer from 1994 to 2015. Data on the symptoms (**A**), physical signs (**B**), nodule multiplicity (**C**), ultrasonographic sizes of nodules (**D**), FNA ratio (**E**), and thyroidectomy types (**F**) were summarized.

**Figure 3.** Determinant factors of lymph node metastasis of PTC (**A**), mPTC (**B**) and crPTC (**C**). Logistic regression was performed to define factors associated with local lymph node metastasis.

For peer review only




Figure 1

94x111mm (600 x 600 DPI)




Figure 2

237x332mm (300 x 300 DPI)






Figure 3

170x313mm (300 x 300 DPI)

# BMJ Open

## Features and Trends of Thyroid Cancer in Patients with Thyroidectomies in Beijing, China between 1994 and 2015

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023334.R1
Article Type:	Research
Date Submitted by the Author:	27-Jul-2018
Complete List of Authors:	Zhao, Ling; PLA General Hospital, Endocrinology and Metabolism Pang, Ping; Hainan Branch of PLA General Hospital, Endocrinology Zang , Li; PLA General Hospital, Endocrinology and Metabolism Luo, Yukun; PLA General Hospital, Ultrasonography Wang, Fulin; PLA General Hospital, Pathology Yang, Guoqing; PLA General Hospital, Endocrinology and Metabolism Du, Jin; PLA General Hospital, Endocrinology and Metabolism Wang, Xianling; PLA General Hospital, Endocrinology and Metabolism Lyu, Zhaohui; Department of Endocrinology, Chinese People's Liberation Army General Hospital Dou , Jingtao; PLA General Hospital, Endocrinology and Metabolism Yiming, Mu; Chinese People's Liberation Army (PLA) General Hospital , Endocrinology and Metabolism
<b>Primary Subject Heading</b>:	Ear, nose and throat/otolaryngology
Secondary Subject Heading:	Ear, nose and throat/otolaryngology
Keywords:	Thyroid cancer, Papillary thyroid carcinoma, microPTC

SCHOLARONE™  
Manuscripts

1  
2  
3 **Features and Trends of Thyroid Cancer in Patients with Thyroidectomies in Beijing,**  
4  
5 **China between 1994 and 2015**  
6  
7

8  
9 **Running Title:** Evolution of thyroid cancer in China  
10

11  
12  
13 Ling Zhao <sup>1#</sup>, Ping Pang <sup>2#</sup>, Li Zang <sup>1</sup>, Yukun Luo <sup>3</sup>, Fulin Wang <sup>4</sup>, Guoqing Yang <sup>1</sup>, Jin Du<sup>1</sup>,  
14  
15 Xianling Wang <sup>1</sup>, Zhaohui Lyu <sup>1\*</sup>, Jingtao Dou <sup>1</sup>, Yiming Mu <sup>1</sup>  
16  
17

18  
19  
20 <sup>1</sup> The Department and Key Laboratory of Endocrinology and Metabolism, PLA General  
21  
22 Hospital, Beijing, 100853, China;  
23

24 <sup>2</sup> Department of Endocrinology, Hainan Branch of PLA General Hospital, Sanya, 572013,  
25  
26 Hainan, China;  
27

28 <sup>3</sup> Department of Ultrasonography, PLA General Hospital, Beijing, 100853, China;  
29

30 <sup>4</sup>Department of Pathology, PLA General Hospital, Beijing, 100853, China.  
31  
32

33  
34  
35 **\*Corresponding author:**  
36

37 Zhao-hui Lyu, MD  
38

39 Department of Endocrinology, PLA General Hospital, No. 28, Fuxing Road, Haidian District,  
40  
41 Beijing, 100853, China  
42

43  
44 Tel: +86 186 1011 1788, Email: metabolism301@126.com  
45  
46

47  
48 <sup>#</sup> These authors contributed equally to the study  
49  
50

51  
52 **Keyword:** Thyroid cancer; Papillary thyroid carcinoma; microPT4C  
53  
54  
55  
56



## Abstract

**Objectives:** This study aims to summarize the features and trends of thyroid carcinoma in the past two decades in China.

**Design, Setting and Participants:** Clinical data obtained from 10,798 patients treated by thyroidectomy from 1994 to 2015 at the Department of General Surgery of the People's Liberation Army General Hospital, Beijing, China were retrospectively analyzed.

**Outcome measures:** Incidence and histopathological features of thyroid cancer were compared and the risk factors for local lymph node metastasis analyzed.

**Results:** Our data indicated a significant increase in the detection of thyroid cancer (from 16.8% to 69.8%,  $P < 0.01$ ). Among the 5,235 thyroid cancer cases, papillary thyroid carcinoma (PTC) was the most common histotype, accounting for 95.1% of all malignancies over the 22-year period. Among the 4,979 PTCs, microPTCs (mPTC) with the largest diameter  $\leq 10$  mm has gradually become the dominant form, and its percentage in PTCs has increased from 13.3% in the biennial period of 1994-1995 to 51.2% in 2010-2011. Furthermore, the size of the tumor has decreased significantly from  $2.3 \pm 1.1$  cm in 1994 to  $1.2 \pm 0.9$  cm in the largest diameter ( $P < 0.01$ ), while the average age at diagnosis and female dominance remained unchanged during the period. Logistic regression showed that tumor nodules  $> 1$  cm and male gender were the main risk factors for local lymph node metastasis (LNM) whereas patients over 45 years old had lower risk.

**Conclusions:** During the 22-year period, an increased detection of thyroid cancer, particularly mPTC, was found while the occurrence of LNM decreased. Our results suggest that the current preoperative diagnosis and risk stratification are adequate, supporting the published guidelines for the diagnosis of thyroid cancer.

### Strengths and limitations of this study

- The strength of this study lies in that more than 10,000 cases of thyroid cancer over a period of 22 years were retrospectively studied to summarize the features and trends of thyroid cancer in patients with thyroidectomies in Beijing, China.
- The clinical practice was reviewed over this long period of time to evaluate the performance of the preoperative diagnosis and risk stratification in a major hospital in Beijing.
- The retrospective nature of this study led to limited survival data, which should have been included to evaluate the improvement of clinical outcome during the 22-year period.

## Introduction

Thyroid nodules occur in about 4-7% of the population, and 8-16% of these contain malignant elements <sup>1</sup>. Thyroid cancer is the most common endocrine cancer <sup>1</sup>, and approximately 90% of these are differentiated, including predominantly papillary thyroid carcinoma (PTC) and, to a less extent, follicular thyroid carcinoma <sup>2</sup>. These subtypes are generally associated with a more favorable prognosis and higher cure rate <sup>3</sup>, when compared with less common but more aggressive forms of thyroid cancer, such as medullary thyroid cancer, anaplastic thyroid cancer, and thyroid sarcoma or lymphoma <sup>4</sup>.

The past few decades have witnessed an increase in the incidence of thyroid cancer, while the associated mortality remains unchanged <sup>5-9</sup>. In addition, the number of newly diagnosed thyroid cancer cases with smaller tumors increased. Between 2008 and 2009, 39% of thyroid cancer patients were diagnosed with tumors smaller than 1 cm, when compared to 25% of patients diagnosed between 1988 and 1989 <sup>10</sup>. This was due to the proactive screening of thyroid cancer, particularly through the application of sensitive surveillance modalities in recent years <sup>11-15</sup>. Advanced imaging techniques, such as ultrasonography, computational tomography, magnetic resonance imaging and positron emission tomography, along with fine-needle aspiration biopsy have dramatically improved the detection of small thyroid nodules, and facilitated the early diagnosis of thyroid cancer <sup>16-18</sup>.

However, the increased incidence of thyroid cancer has also been considered to be associated with over-diagnosis <sup>18-22</sup> and environmental factors <sup>6,23</sup>. The screening of highly prevalent thyroid nodules for those with malignant potential remains challenging, although a number of guidelines have recently been proposed for the diagnosis and management of thyroid nodules <sup>24</sup>. Identifying nodules with high risk of malignancy during thyroidectomy represents a cost-effective approach <sup>25,26</sup>. Therefore, in this study, the features and trends of thyroid cancer in patients with thyroidectomies in China were retrospectively analyzed to

1  
2  
3 examine whether the decrease in diagnosable size of thyroid nodules is associated with  
4  
5 misdiagnosis, providing further insight into its diagnosis and management.  
6  
7  
8

## 9 **Materials and Methods**

10  
11 This study was approved by the Chinese People's Liberation Army (PLA) General  
12 Hospital Ethics Committee, and written informed consents obtained from all patients for  
13 retrospective studies.  
14  
15  
16  
17  
18  
19

### 20 ***Data collection***

21  
22 The clinical database for patients undergoing thyroidectomies from 1994 to 2015 at the  
23 Department of General Surgery of PLA General Hospital (Beijing, China) was revisited, and  
24 the thyroid pathology reports were screened and reviewed to analyze the correlation of the  
25 size of thyroid nodules with other pathological features.  
26  
27  
28  
29  
30

31 The clinical parameters used in the analysis included front neck discomfort or pain,  
32 dysphagia, dysphonia or hoarseness, dyspnea, sign of thyroid nodule and thyroid gland  
33 enlargement, as well as ultrasound features. These data were individually checked, and cases  
34 with inconsistent data were excluded before the statistical analysis. As a result, 10,798  
35 eligible cases with thyroidectomies from 1994 to 2015 were recruited.  
36  
37  
38  
39  
40  
41  
42  
43

### 44 ***Data analysis and statistics***

45  
46 Benign or malignant thyroid nodules were diagnosed based on pathological features, and  
47 malignant nodules were reported as papillary (PTC), follicular (FTC), medullary (MTC), or  
48 anaplastic thyroid carcinoma (ATC). Papillary thyroid carcinomas were further sub-classified  
49 into clinically relevant PTCs (crPTCs) >10 mm in diameter and micro-PTCs (mPTCs) ≤10  
50 mm in diameter (the largest diameter of a nodule). These sub-groups were compared, when  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 appropriate, in the analysis.  
4

5 Patients were treated by surgery, often with lymph node dissection, depending on the  
6 clinical features and the number, location and size of the involved lymph node, which was  
7 assessed by pre-operative imaging analysis and intraoperative frozen section pathological  
8 analysis. Tumors within 10 mm in size and had no involvement of lymph nodes were resected  
9 without the removal of lymph nodes. When the pre-operative imaging revealed no  
10 abnormalities in the lymph nodes, but malignancy was confirmed by intraoperative frozen  
11 section analysis, ipsilateral central neck node dissection was performed. If the preoperative  
12 sonography or intraoperative examination revealed abnormal lymph nodes, and frozen  
13 section analysis confirmed the malignancy, improved lateral neck lymph node dissection was  
14 performed.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 Statistical analysis was performed using the Statistical Package for the Social Sciences  
27 (SPSS, Version 17.0; IBM, Armonk, NY). Data were presented as mean  $\pm$  standard deviation  
28 or mean  $\pm$  standard error, when appropriate. Chi-square test was used to compare different  
29 categories and generate the trend lines. Furthermore, *t*-test was used for comparisons between  
30 groups, and logistic regression was performed to calculate the risk factors for lymph node  
31 metastasis (LNM). The data analysis was adjusted for confounders, such as age, gender,  
32 nodule size and the presence of Hashimoto thyroiditis. A two-tailed  $P < 0.05$  was considered  
33 statistically significant.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

#### 46 ***Patient and public involvement***

47

48 This retrospective study did not involve patients or the public in the development of  
49 research initiatives and outcome measures, as well as the design and implementation of the  
50 study. The study covered a period of 22 years, which ranged between 1994 and 2015.  
51  
52  
53  
54 Therefore, there was no possibility or plan to disseminate the results among the participants.  
55  
56  
57  
58  
59  
60

## Results

### *Malignancy rate increased from 1994 to 2015*

The numbers of benign and malignant cases of thyroid cancer detected during thyroidectomy from 1994 to 2015 are summarized in Table 1. As the number of thyroidectomy surgeries increased due to the improved diagnosis of thyroid cancer, the number of benign and malignant cases gradually increased. Noticeably, the malignancy rate of thyroid nodules dramatically increased from 16.8% during the biennial period of 1994-1995 to 69.8% during the period of 2014-2015 ( $P<0.05$ ), while the benign rate decreased from 83.2% to 30.2% ( $P<0.05$ ).

### *The diagnosis rate of PTC increased from 1994 to 2015*

Among the 10,798 cases recruited, 5,235 cases were found to be malignant (Table 2). Furthermore, a majority of patients (63.6%) were found with multiple cancers. Moreover, 48.1% of patients had unilateral cancer, and the remaining 51.9% of patients had bilateral cancer (Table 2). In addition, most of the malignant cases were recorded as PTCs, which exhibited a significant increase from 65.3% during the period of 1994-1995 to 98.2% during the period of 2014-2015 ( $P<0.05$ , Figure 1), while the diagnosis rates of other histotypes concurrently decreased (Table 2 and Figure 1).

### *Detection size of thyroid nodules decreased from 1994 to 2015*

The review of the clinicopathological information of malignant cases suggested that most of these patients were free of clinically relevant symptoms and physical signs (Figures 2A and 2B), and only 9% of patients exhibited different degrees of discomfort, such as pain and dysphagia. The enlargement of thyroid glands were often noticed, but not necessarily by health professionals, during routine physical examination. However, 34% of tumors were

1  
2  
3 impalpable, which was likely due to the depth of the intra-thyroidal microcarcinoma. By  
4 ultrasonography, 37% of patients were detected with single thyroid tumors, while the  
5 remaining patients had multiple lesions (Figure 2C).  
6  
7

8  
9 From 1994 to 2015, the size of thyroid nodules has been reported to significantly  
10 decrease, with the mean diameter reduced from  $2.6 \pm 1.4$  cm to  $1.2 \pm 0.9$  cm (Figure 2D).  
11 This trend roughly correlates with the increase in the rate of preoperative fine needle  
12 aspiration (FNA), which ranged from 15% in 2004 to 74% in 2013, although this rate  
13 regressed to 57% between 2014 and 2015 (Figure 2E). In addition, during the same period,  
14 the total thyroidectomy rate remained unchanged from 1994 to 2007, but gradually increased  
15 from 2008 to 2013, and decreased sharply to 3% from 2014 to 2015 (Figure 2F).  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

### 26 ***The size of the thyroid cancer at diagnosis and metastasis rate decreased from 1994 to 2015***

27  
28 Considering the high prevalence of PTCs, 4,980 cases were compared to 255 cases of  
29 other subtypes all-together, and further data analysis was restricted to this type of thyroid  
30 cancer. As shown in Table 3, the mean age of patients at diagnosis was  $43.7 \pm 11.3$  years old,  
31 with no significant variation from 1994 to 2015. Furthermore, the incidence of PTC was  
32 considerably higher in women than in men, in which approximately two thirds of these  
33 patients were female. It is noteworthy that the average diameter of PTCs at diagnosis  
34 decreased from  $2.3 \pm 1.1$  cm in 1994 to  $1.2 \pm 0.9$  cm in 2015 ( $P < 0.05$ , Table 3). Correlating  
35 with this trend was the increase in the percentage of mPTCs from 13.3% between 1994 and  
36 1995 to 51.2% between 2010 and 2011 ( $P < 0.05$ , Table 3). This likely resulted from a more  
37 meticulous pathological examination. Interestingly, the detection rate of mPTCs decreased to  
38 26.5 between 2014 and 2015.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

52 Among the PTC cases studied, 1,212 patients were found with LNM, but its occurrence  
53 significantly decreased with the reduction in tumor size ( $P < 0.05$ , Table 3). This was  
54  
55  
56

1  
2  
3 associated with the increased diagnosis rate of mPTCs, which shows an apparently lower  
4 LNM potential in comparison with crPTCs (Table 4). Before 2007, the difference between the  
5 LNM rates of mPTC and crPTC were appreciable, but this not statistically significant most of  
6 time due to the limited size of the cohort. With the increase in PTC diagnosis after 2008, a  
7 significantly lower LNM occurrence was found for mPTCs, when compared to crPTCs  
8 (Table 4).  
9  
10  
11  
12  
13  
14  
15  
16  
17

### 18 ***Determinant factors of local lymph node metastasis in PTC, mPTC and crPTC***

19  
20 To identify the risk factors for local LNM in PTC, mPTC and crPTC, a logistic  
21 regression analysis was performed. The results support the correlation of LNM with  
22 nodules >1 cm (odd ratio [OR]: 2.480, confidence interval [CI]: 0.428 – 0.613;  $P<0.001$ ) and  
23 male gender (OR: 1.627, CI: 1.376-1.923;  $P<0.001$ ), and its inverse correlation with the age  
24 of  $\geq 45$  years old (OR: 0.512, CI: 2.040-2.902;  $P<0.001$ ) after adjustment for other covariates  
25 in all PTCs (Figure 3A, Table 2). Hashimoto's thyroiditis presented no risk for LNM (Figure  
26 3A). Consistent data were also obtained from patients with mPTC and crPTC (Figures 3B  
27 and 3C; Tables 3 and 4).  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

### 41 **Discussion**

42 Thyroid cancer is diagnosed in nearly 300,000 people annually all over the world <sup>27</sup>.  
43 Although these malignancies are mostly differentiated and generally associated with a good  
44 prognosis, the involvement of local lymph nodes is frequently observed. Proactive screening  
45 for malignancies from a substantial population of thyroid nodes and accurate  
46 histopathological stratification are crucial for the clinical decision and improvement of  
47 patient outcome. The present study reviewed 10,798 cases of thyroidectomy undertaken in a  
48 major hospital located in one of the most populated city in the world for a period of over 22  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 years, summarized the clinical features of 5,235 cases of thyroid cancer, and analyzed the  
4  
5 trend of PTCs and risk factors for predicting LNM.  
6

7 The present analysis unveiled a gradual but significant increase in thyroid malignancy  
8  
9 detection rate between the period of 1994 and 2015, which ranged from 16.8% to 69.8%.  
10  
11 These percentages are generally within the wide-range detection rate (6.7-56%) of thyroid  
12  
13 cancer worldwide <sup>25 28 29</sup>, although data between 2014 and 2015 was relatively higher than  
14  
15 earlier periods. Furthermore, the detection rates varied across different centers, which were  
16  
17 likely caused by the different guidelines and algorithms followed by physicians and surgeons.  
18  
19 The increase in detection rate from 1994 to 2015 reflects the improvement in diagnosis  
20  
21 through the advances in imaging technology, and the increasing use of FNA. In addition, the  
22  
23 appropriate preoperative risk stratification of thyroid nodules, which was a result of improved  
24  
25 clinical evaluation, thyroid function test, ultrasonography and molecular diagnosis in recent  
26  
27 years, has diverted a lot of patients from thyroidectomy, contributing to the increased  
28  
29 diagnosis of thyroid cancer. These data support published guidelines <sup>30 31</sup> and highlights the  
30  
31 importance of combining imaging, FNA, cytology and molecular diagnosis. However, the  
32  
33 contribution of social and environmental stresses could not be rule out, which is beyond the  
34  
35 scope of the present retrospective study. It is noteworthy that the present study covered a  
36  
37 period during which China was undergoing the largest scale of industrialization in modern  
38  
39 history. This inevitably led to dramatic social and environmental changes.  
40  
41  
42  
43

44 Papillary carcinoma accounts for 95.1% of malignancies in the whole cohort, and  
45  
46 reached as high as 98.2% among patients diagnosed between 2014 and 2015. These rates  
47  
48 were comparable to the findings of another study performed in Nanjing, China <sup>25</sup>, but were  
49  
50 higher than those in other reports <sup>32</sup>, which was likely due to the increase in PTCs, as  
51  
52 previously suggested <sup>33</sup>. The high detection rate for PTC was attributable to the increasing  
53  
54 use of head and neck imaging, which detects sub-palpable (yet potentially malignant) thyroid  
55  
56

1  
2  
3 nodules, and ultrasound-guided FNA, which improves the preoperative detection of  
4 malignancy. With the use of neck ultrasonography and other diagnostic approaches, the  
5 average size of PTCs at diagnosis has significantly reduced from  $2.3 \pm 1.1$  cm in 1994 to  $1.2$   
6  $\pm 0.9$  cm in 2015, and this was similar to the trends reported in previous studies<sup>10 25</sup>. This  
7 progress allows for the early detection of thyroid cancer, which leads to the increasing trend  
8 of hemithyroidectomy, when compared to total thyroidectomy, and the intensified follow-up  
9 of thyroid cancer patients in recent years in our practice following the American Thyroid  
10 Association (ATA) guidelines<sup>30 31 33</sup>. However, the overdiagnosis and overtreatment of  
11 indolent diseases have been increasingly recognized. The most recent ATA guidelines suggest  
12 a more parsimonious evaluation of thyroid nodules and a more judicious use of thyroid  
13 cancer treatment, in order to minimize risk and maximize benefits to patients<sup>33</sup>.

14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27 The present data suggests that nodules  $>1$  cm and the male gender predict a high risk of  
28 LNM, while the age of  $\geq 45$  years old is associated with low LNM potentials, and this is  
29 consistent with a previous finding<sup>25</sup>. Therefore, more attention is needed for these patients in  
30 future practice. However, in this single-center study, factors taken into account for the logistic  
31 regression analysis were limited due to the retrospective nature of the study. Future studies  
32 are needed to characterize the association of other clinical and biochemical parameters with  
33 thyroid cancer metastasis and patient outcome. Characterizing the contribution of social and  
34 environmental stresses to the occurrence of thyroid cancer would also be of significant social  
35 economical value.

36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46 In the present study, the clinical data of 10,798 patients treated by thyroidectomy was  
47 retrospectively analyzed to determine the features and trends of thyroid cancer in the past 22  
48 years. The present data suggested a significant increase in the detection rate of thyroid cancer,  
49 particularly mPTC, which has become the dominant form of thyroid cancer. As a result, the  
50 occurrence of LNM has been decreasing with time. The present results suggest the adequacy

1  
2  
3 of present preoperative diagnosis and risk stratification, although overdiagnosis and  
4  
5 overtreatment require future attention of physicians and surgeons in view of the rapid  
6  
7 increase in the number of thyroidectomies.  
8  
9

## 10 11 **Acknowledgements**

12  
13 We gratefully acknowledge the invaluable contribution of the doctors and nurses of  
14  
15 Chinese PLA General Hospital and the patients involved in this study.  
16  
17

## 18 19 **Funding**

20  
21 This study was supported by a grant from the Medical Science and Technology  
22  
23 Foundation of the Military “Twelve-Five” Program (CWS11J063) to ZHL  
24  
25  
26  
27

## 28 29 **Authors' contributions**

30  
31 ZL designed the study, collected and analyzed data, and wrote the manuscript. PP  
32  
33 contributed in writing the manuscript. ZL, LYK, WFL, YGQ, DJ and WXL assisted with the  
34  
35 data presentation and manuscript writing. LZH, DJT and MYM contributed in the study  
36  
37 design, data analysis and manuscript writing. All authors read and approved the final  
38  
39 manuscript.  
40  
41  
42  
43

## 44 45 **Competing interests**

46 The authors have no conflicts of interest to disclose.  
47  
48  
49

## 50 51 **Data sharing statement**

52 Data will be available upon request to the corresponding author  
53  
54  
55  
56  
57

## References

1. Burman KD, Wartofsky L. CLINICAL PRACTICE. Thyroid Nodules. *N Engl J Med* 2015;373:2347-56.
2. Ron E, Schneider AB. Thyroid Cancer In: Schottenfeld D, Jr. FJF, eds. *Cancer Epidemiology and Prevention* New York: Oxford University Press, 2006:975-94.
3. Schlumberger MJ. Papillary and follicular thyroid carcinoma. *N Engl J Med* 1998;338:297-306.
4. Spielman DB, Badhey A, Kadakia S, et al. Rare Thyroid Malignancies: an Overview for the Oncologist. *Clin Oncol (R Coll Radiol)* 2017;29:298-306.
5. Brito JP, Kim HJ, Han SJ, et al. Geographic Distribution and Evolution of Thyroid Cancer Epidemic in South Korea. *Thyroid* 2016;26:864-5.
6. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. *Cancer Epidemiol Biomarkers Prev* 2009;18:784-91.
7. Pandeya N, McLeod DS, Balasubramaniam K, et al. Increasing thyroid cancer incidence in Queensland, Australia 1982-2008 - true increase or overdiagnosis? *Clin Endocrinol (Oxf)* 2015.
8. Uhry Z, Colonna M, Remontet L, et al. Estimating infra-national and national thyroid cancer incidence in France from cancer registries data and national hospital discharge database. *Eur J Epidemiol* 2007;22:607-14.
9. Wang Y, Wang W. Increasing incidence of thyroid cancer in Shanghai, China, 1983-2007. *Asia Pac J Public Health* 2015;27:NP223-9.
10. Davies L, Welch HG. Current thyroid cancer trends in the United States. *JAMA Otolaryngol Head Neck Surg* 2014;140:317-22.
11. Brito JP, Gionfriddo M, Morris JC, et al. Overdiagnosis of thyroid cancer and graves'

- disease. *Thyroid* 2014;24:402-3.
12. Brito JP, Hay ID, Morris JC. Low risk papillary thyroid cancer. *BMJ* 2014;348:g3045.
13. Brito JP, Morris JC, Montori VM. Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. *BMJ* 2013;347:f4706.
14. Kilfoy BA, Zheng T, Holford TR, et al. International patterns and trends in thyroid cancer incidence, 1973-2002. *Cancer Causes Control* 2009;20:525-31.
15. Trimboli P, Guglielmi R, Monti S, et al. Ultrasound sensitivity for thyroid malignancy is increased by real-time elastography: a prospective multicenter study. *J Clin Endocrinol Metab* 2012;97:4524-30.
16. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. *JAMA* 2006;295:2164-7.
17. Kent WD, Hall SF, Isotalo PA, et al. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. *CMAJ* 2007;177:1357-61.
18. Sosa JA, Hanna JW, Robinson KA, et al. Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States. *Surgery* 2013;154:1420-6; discussion 6-7.
19. Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic"--screening and overdiagnosis. *N Engl J Med* 2014;371:1765-7.
20. Brito JP, Davies L. Is there really an increased incidence of thyroid cancer? *Curr Opin Endocrinol Diabetes Obes* 2014;21:405-8.
21. Franceschi S, Vaccarella S. Thyroid cancer: an epidemic of disease or an epidemic of diagnosis? *Int J Cancer* 2015;136:2738-9.
22. Morris LG, Tuttle RM, Davies L. Changing Trends in the Incidence of Thyroid Cancer in the United States. *JAMA Otolaryngol Head Neck Surg* 2016;142:709-11.
23. Aschebrook-Kilfoy B, Grogan RH. Re: Brito et al., overdiagnosis of thyroid cancer and

- 1  
2  
3 Graves' disease. *Thyroid* 2014;24:403-4.  
4  
5 24. Paschke R, Hegedus L, Alexander E, et al. Thyroid nodule guidelines: agreement,  
6  
7 disagreement and need for future research. *Nat Rev Endocrinol* 2011;7:354-61.  
8  
9 25. Liu X, Zhu L, Wang Z, et al. Evolutionary features of thyroid cancer in patients with  
10  
11 thyroidectomies from 2008 to 2013 in China. *Sci Rep* 2016;6:28414.  
12  
13 26. Liu XY, Zhu LJ, Cui D, et al. Annual financial impact of thyroidectomies for nodular  
14  
15 thyroid disease in China. *Asian Pac J Cancer Prev* 2014;15:5921-6.  
16  
17 27. La Vecchia C, Malvezzi M, Bosetti C, et al. Thyroid cancer mortality and incidence: a  
18  
19 global overview. *Int J Cancer* 2015;136:2187-95.  
20  
21 28. Wienhold R, Scholz M, Adler JR, et al. The management of thyroid nodules: a  
22  
23 retrospective analysis of health insurance data. *Dtsch Arztebl Int* 2013;110:827-34.  
24  
25 29. Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary  
26  
27 approach to thyroid nodule diagnostic evaluation. *Cancer* 2007;111:508-16.  
28  
29 30. American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated  
30  
31 Thyroid C, Cooper DS, et al. Revised American Thyroid Association management  
32  
33 guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid*  
34  
35 2009;19:1167-214.  
36  
37 31. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with  
38  
39 thyroid nodules and differentiated thyroid cancer. *Thyroid* 2006;16:109-42.  
40  
41 32. Othman NH, Omar E, Naing NN. Spectrum of thyroid lesions in hospital Universiti Sains  
42  
43 Malaysia over 11years and a review of thyroid cancers in Malaysia. *Asian Pac J*  
44  
45 *Cancer Prev* 2009;10:87-90.  
46  
47 33. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association  
48  
49 Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated  
50  
51 Thyroid Cancer: The American Thyroid Association Guidelines Task Force on  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1-133.  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table 1. Detection rate of malignancy among patients undergoing thyroidectomy from 1994 to 2015**

Period	94.1-95.12	96.1-97.12	98.1-99.12	00.1-01.12	02.1-03.12	04.1-05.12	06.1-07.12	08.1-09.12	10.1-11.12	12.1-13.12	14.1-15.12	Total	<i>P</i>
Benign, <i>n</i> 114	136	169	268	286	495	535	738	901	1033	890	5563	<0.001	
(%)	(83.2)	(86.1) <sup>a,b</sup>	(88.0) <sup>a,b</sup>	(83.0) <sup>a</sup>	(80.1) <sup>a,b</sup>	(79.2) <sup>b</sup>	(71.4) <sup>a,b</sup>	(64.6) <sup>a,b</sup>	(52.4) <sup>a,b</sup>	(42.2) <sup>a,b</sup>	(30.2) <sup>a,b</sup>	(51.5)	
Cancer, <i>n</i> 23	22	23	55	71	130	214	405	817	1413	2060	5235		
(%)	(16.8)	(13.9) <sup>a,b</sup>	(12.0) <sup>a,b</sup>	(17.0) <sup>a</sup>	(19.9) <sup>a,b</sup>	(20.8) <sup>b</sup>	(28.6) <sup>a,b</sup>	(35.4) <sup>a,b</sup>	(47.6) <sup>a,b</sup>	(57.8) <sup>a,b</sup>	(69.8) <sup>a,b</sup>	(48.5)	
Total	137	158	192	323	357	625	749	1143	1718	2446	2950	10798	

<sup>a</sup> Percentages significantly different from the previous year; <sup>b</sup> Percentages significantly different within the period of 94.1-95.12.



**Table 2. Pathological classification of all thyroid malignancies from 1994 to 2015**

Period	94.1- 95.12	96.01- 97.12	98.1- 99.12	00.1- 01.12	02.1- 03.12	04.1- 05.12	06.1- 07.12	08.1- 09.12	10.1- 11.12	12.1- 13.12	14.1- 15.12	<i>P</i> for difference	<i>P</i> for trend
PTC, <i>n</i> (%)	15 (65.3)	17 (77.3)	17 (73.9)	39 (70.9)	50 (70.4)	107 (82.3)	185 (86.4)	383 (94.6)	768 (94.0)	1376 (97.4)	2023 (98.2)	<0.001	<0.001
FTC, <i>n</i> (%)	3 (13.0)	1 (4.5)	4 (17.3)	10 (18.1)	9 (12.7)	17 (13.1)	18 (8.4)	9 (2.2)	25 (3.0)	17 (1.2)	20 (0.9)	<0.001	<0.001
MTC, <i>n</i> (%)	1 (4.3)	2 (9.1)	1 (4.3)	4 (7.3)	2 (2.8)	1 (0.8)	2 (0.9)	5 (1.2)	14 (1.7)	12 (0.8)	12 (0.6)	<0.001	<0.001
ATC, <i>n</i> (%)	0 (0)	0 (0)	1 (4.3)	1 (1.8)	3 (4.2)	1 (0.8)	1 (0.5)	2 (0.5)	1 (0.1)	1 (0.1)	2 (0.1)	<0.001	<0.001
Other, <i>n</i> (%)	4 (17.4)	2 (9.1)	0 (0)	1 (1.8)	7 (9.9)	4 (3.1)	7 (3.3)	6 (1.5)	9 (1.1)	7 (0.5)	3 (0.1)	<0.001	<0.001
Unilateral	14 (60.9)	14 (63.6)	13 (56.5)	31 (56.4)	38 (53.5)	72 (55.4)	122 (57.0)	213 (52.6)	389 (47.6)	616 (43.6)	991 (48.1)	0.071	<0.001
Bilateral	9 (39.1)	8 (36.4)	10 (43.5)	24 (43.6)	33 (46.5)	58 (44.6)	92 (43.0)	192 (47.4)	428 (52.4)	797 (56.4)	1069 (51.9)		
Solitary	7 (30.4)	13 (59.1)	11 (47.8)	27 (49.1)	28 (39.4)	59 (45.4)	105 (49.0)	172 (42.5)	292 (35.7)	456 (32.3)	749 (36.4)	<0.001	<0.001
Multiple	16 (69.6)	9 (40.9)	12 (52.2)	28 (50.9)	43 (60.6)	71 (54.6)	109 (51.0)	233 (57.5)	525 (64.3)	957 (67.7)	1311 (63.6)		
All cancer, <i>n</i>	23	22	23	55	71	130	214	405	817	1413	2060		

PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; MTC, medullary thyroid carcinoma; ATC, anaplastic thyroid carcinoma; other histotypes of carcinoma collectively refer to cancer other than PTC, FTC, MTC and ATC, including poorly differentiated thyroid cancer, squamous cell carcinomas, B cell lymphomas of thyroid, spindle cell carcinoma, adenoid cystic carcinoma, renal clear cell metastasis and Langerhans cell histiocytosis of the thyroid gland.

**Table 3. Clinicopathological features of PTCs from 1994 to 2015**

Period	94.1- 95.12	96.1- 97.12	98.1- 99.12	00.1- 01.12	02.1- 03.12	04.1- 05.12	06.1- 07.12	08.1- 09.12	10.1- 11.12	12.1- 13.12	14.1- 15.12	Total	<i>P</i> for difference	<i>P</i> for trend
Age, year	46.9±14.3	43.1±10.7	41.1±12.9	44.9±14.8	44.6±14.5	43.8±12.4	44.6±12.4	42.7±12.4	43.9±11.2	43.9±11.1	43.6±10.9	43.7±11.3	0.643	
Male, <i>n</i>	5	3	6	11	18	34	60	115	227	366	616	1461	0.434	0.664
(%)	(33.3)	(17.6)	(35.3)	(28.2)	(36)	(31.8)	(32.4)	(30.0)	(29.6)	(26.6)	(30.4)	(29.3)		
Female, <i>n</i>	10	14	11	28	32	73	125	268	541	1010	1407	3519		
(%)	(66.7)	(82.4) <sup>ab</sup>	(64.7.0) <sup>a</sup>	(71.8) <sup>a</sup>	(64) <sup>ab</sup>	(68.2) <sup>b</sup>	(67.6) <sup>ab</sup>	(70.0) <sup>ab</sup>	(70.4) <sup>ab</sup>	(73.4) <sup>a</sup>	(69.6) <sup>a</sup>	(70.7)		
Size <sup>c</sup> , cm	2.3±1.1	2.6±1.9	2.1±1.3	2.2±1.6	2.2±1.4	2.2±1.6	1.7±1.1 <sup>ab</sup>	1.5±1.0 <sup>b</sup>	1.3±0.9 <sup>ab</sup>	1.2±0.8 <sup>ab</sup>	1.2±0.9 <sup>b</sup>	1.4±1.0	<0.001	
CrPTC, <i>n</i>	13	15	12	32	41	87	118	238	375	696	1486	3113	<0.001	0.213
(%)	(86.7)	(88.2)	(70.6)	(82.1)	(82.0)	(81.3)	(63.8) <sup>a</sup>	(62.1) <sup>b</sup>	(48.8) <sup>ab</sup>	(50.6) <sup>b</sup>	(73.5) <sup>a</sup>	(62.5)		
mPTC, <i>n</i>	2	2	5	7	9	20	67	145	393	680	537	1866		
(%)	(13.3)	(11.8)	(29.4)	(17.9)	(18.0)	(18.7)	(36.2)	(37.9)	(51.2)	(49.4)	(26.5)	(37.5)		
LNM, <i>n</i>	5	5	7	22	17	27	55	96	192	372	414	1212	<0.001	<0.001
(%)	(33.3)	(29.4)	(41.2)	(56.4)	(34)	(25.2)	(29.7)	(25.1)	(25.0)	(27.0)	(20.5) <sup>a</sup>	(24.3)		
No-LNM, <i>n</i>	10	12	10	17	33	80	130	287	576	1004	1609	3768		
(%)	(66.7)	(70.6)	(58.8)	(43.6)	(66)	(74.8)	(70.3)	(74.9)	(75.0)	(73.0)	(79.5)	(75.7)		
Total	15	17	17	39	50	107	185	383	768	1376	2023		<0.001	<0.001

1  
2  
3  
4 <sup>a</sup> Percentages significantly different from the previous year; <sup>b</sup> Percentages significantly different within the period of 08.1-09.12; <sup>c</sup> Mean diameter;  
5  
6 crPTC, clinical relevant papillary thyroid carcinoma; mPTC, micro papillary thyroid carcinoma; LNM, lymph node metastasis; LN, lymph node.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

For peer review only

**Table 4. Rate of local lymph node metastasis in patients with crPTC and mPTC from 2008 to 2013**

	94.1	96.1	98.1	00.1	02.1	04.1	06.1	08.1	10.1	12.1	14.1	Total	<i>P</i> for	<i>P</i> for
	-95.12	-97.12	-99.12	-01.12	-03.12	-05.12	-07.12	-09.12	-11.12	-13.12	-15.12		difference	trend
crPTC, <i>n</i> (%)	3 (23.1)	5 (33.3)	6 (50.0)	19 (59.4)	17 (41.5)	24 (27.6)	35 (29.7)	73 (30.7)	130 (34.7)	243 (34.9)	330 (22.2)	885 (28.4)	<0.001	<0.001
mPTC, <i>n</i> (%)	2 (100)	0 (0)	1 (20.0)	3 (42.9)	0 (0)	3 (15.0)	20 (29.9)	23 (16.0)	62 (15.8)	129 (19.0)	84 (15.6)	327 (17.5)	0.005	0.087
<i>P</i> -value	0.032	0.331	0.252	0.425	0.017	0.243	0.978	0.001	0.000	0.000	0.001			

crPTC, clinical relevant papillary thyroid carcinoma; mPTC, micro papillary thyroid carcinoma.

## Figure legends

**Figure 1** Trends in the diagnosis of various subtype thyroid malignancies, presented as permillage (rate per thousand) of thyroid cancer, from 1994 to 2015.

**Figure 2** Clinical, surgical and ultrasound features during the evolvement of thyroidectomy and the diagnosis of thyroid cancer from 1994 to 2015. Data on the symptoms (**A**), physical signs (**B**), nodule multiplicity (**C**), ultrasonographic sizes of nodules (**D**), FNA ratio (**E**), and thyroidectomy types (**F**) were summarized.

**Figure 3** Determinant factors of the lymph node metastasis of PTC (**A**), mPTC (**B**) and crPTC (**C**). Logistic regression was performed to define factors associated with local lymph node metastasis.




Figure 1

98x108mm (600 x 600 DPI)




Figure 2 (Revised)

211x262mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60






Figure 3

170x313mm (300 x 300 DPI)



## STROBE (Strengthening The Reporting of OBServational Studies in Epidemiology) Checklist

A checklist of items that should be included in reports of observational studies. You must report the page number in your manuscript where you consider each of the items listed in this checklist. If you have not included this information, either revise your manuscript accordingly before submitting or note N/A.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

Section and Item	Item No.	Recommendation	Reported on Page No.
Title and Abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1&2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/Rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
<b>Methods</b>			
Study Design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5&6
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	NA
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	NA
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	NA
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5&6

Section and Item	Item No.	Recommendation	Reported on Page No.
Data Sources/ Measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5&6
Bias	9	Describe any efforts to address potential sources of bias	NA
Study Size	10	Explain how the study size was arrived at	
Quantitative Variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5&6
Statistical Methods	12	(a) Describe all statistical methods, including those used to control for confounding	5&6
		(b) Describe any methods used to examine subgroups and interactions	5&6
		(c) Explain how missing data were addressed	5&6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	NA
		(e) Describe any sensitivity analyses	NA
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive Data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	NA
Outcome Data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	7-9
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	NA
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	NA

Section and Item	Item No.	Recommendation	Reported on Page No.
Main Results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-9
		(b) Report category boundaries when continuous variables were categorized	7-9
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other Analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
<b>Discussion</b>			
Key Results	18	Summarise key results with reference to study objectives	9-10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10-11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-11
Generalisability	21	Discuss the generalisability (external validity) of the study results	NA
<b>Other Information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Once you have completed this checklist, please save a copy and upload it as part of your submission. DO NOT include this checklist as part of the main manuscript document. It must be uploaded as a separate file.**

# BMJ Open

## Features and Trends of Thyroid Cancer in Patients with Thyroidectomies in Beijing, China between 1994 and 2015 – a Retrospective Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023334.R2
Article Type:	Research
Date Submitted by the Author:	30-Oct-2018
Complete List of Authors:	Zhao, Ling; PLA General Hospital, Endocrinology and Metabolism Pang, Ping; Hainan Branch of PLA General Hospital, Endocrinology Zang , Li; PLA General Hospital, Endocrinology and Metabolism Luo, Yukun; PLA General Hospital, Ultrasonography Wang, Fulin; PLA General Hospital, Pathology Yang, Guoqing; PLA General Hospital, Endocrinology and Metabolism Du, Jin; PLA General Hospital, Endocrinology and Metabolism Wang, Xianling; PLA General Hospital, Endocrinology and Metabolism Lyu, Zhaohui; Department of Endocrinology, Chinese People's Liberation Army General Hospital Dou , Jingtao; PLA General Hospital, Endocrinology and Metabolism Yiming, Mu; Chinese People's Liberation Army (PLA) General Hospital , Endocrinology and Metabolism
<b>Primary Subject Heading</b>:	Ear, nose and throat/otolaryngology
Secondary Subject Heading:	Ear, nose and throat/otolaryngology
Keywords:	Thyroid cancer, Papillary thyroid carcinoma, microPTC

SCHOLARONE™  
Manuscripts

1  
2  
3 **Features and Trends of Thyroid Cancer in Patients with Thyroidectomies in Beijing,**  
4  
5 **China between 1994 and 2015 – a Retrospective Study**  
6  
7  
8  
9  
10

11 **Running Title:** Evolution of thyroid cancer in China  
12  
13  
14  
15  
16

17 Ling Zhao <sup>1#</sup>, Ping Pang <sup>2#</sup>, Li Zang <sup>1</sup>, Yukun Luo <sup>3</sup>, Fulin Wang <sup>4</sup>, Guoqing Yang <sup>1</sup>, Jin Du<sup>1</sup>,  
18 Xianling Wang <sup>1</sup>, Zhaohui Lyu <sup>1\*</sup>, Jingtao Dou <sup>1</sup>, Yiming Mu <sup>1</sup>  
19  
20  
21  
22  
23  
24  
25

26 <sup>1</sup> The Department and Key Laboratory of Endocrinology and Metabolism, PLA General  
27 Hospital, Beijing, 100853, China;  
28  
29

30 <sup>2</sup> Department of Endocrinology, Hainan Branch of PLA General Hospital, Sanya, 572013,  
31 Hainan, China;  
32  
33  
34

35 <sup>3</sup> Department of Ultrasonography, PLA General Hospital, Beijing, 100853, China;  
36  
37  
38

39 <sup>4</sup>Department of Pathology, PLA General Hospital, Beijing, 100853, China.  
40  
41  
42  
43  
44

45 **\*Corresponding author:**  
46  
47

48 Zhao-hui Lyu, MD  
49

50  
51 Department of Endocrinology, PLA General Hospital, No. 28, Fuxing Road, Haidian District,  
52 Beijing, 100853, China  
53  
54

55  
56 Tel: +86 186 1011 1788, Email: metabolism301@126.com  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 # These authors contributed equally to the study  
7  
8  
9  
10

11  
12 **Keyword:** Thyroid cancer; Papillary thyroid carcinoma; microPT4C  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Abstract

**Objectives:** This study aims to summarize the features and trends of thyroid carcinoma in the past two decades in China.

**Design, Setting and Participants:** Clinical data obtained from 10,798 patients treated by thyroidectomy from 1994 to 2015 at the Department of General Surgery of the People's Liberation Army General Hospital, Beijing, China were retrospectively analyzed.

**Outcome measures:** Incidence and histopathological features of thyroid cancer were compared and the risk factors for local lymph node metastasis analyzed.

**Results:** Our data indicated a significant increase in the detection of thyroid cancer (from 16.8% to 69.8%,  $P<0.01$ ). Among the 5,235 thyroid cancer cases, papillary thyroid carcinoma (PTC) was the most common histotype, accounting for 95.1% of all malignancies over the 22-year period. Among the 4,979 PTCs, microPTCs (mPTC) with the largest diameter  $\leq 10$  mm has gradually become the dominant form, and its percentage in PTCs has increased from 13.3% in the biennial period of 1994-1995 to 51.2% in 2010-2011. Furthermore, the size of the tumor has decreased significantly from  $2.3\pm 1.1$  cm in 1994 to  $1.2\pm 0.9$  cm in the largest diameter ( $P<0.01$ ), while the average age at diagnosis and female dominance remained unchanged during the period. Logistic regression showed that tumor nodules  $> 1$  cm and male gender were the main risk factors for local lymph node metastasis (LNM) whereas patients over 45 years old had lower risk.

**Conclusions:** During the 22-year period, an increased detection of thyroid cancer, particularly mPTC, was found while the occurrence of LNM decreased. Our results suggest that the current preoperative diagnosis and risk stratification are adequate, supporting the published guidelines for the diagnosis of thyroid cancer.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



### Strengths and limitations of this study

- The strength of this study lies in that more than 10,000 cases of thyroid cancer over a period of 22 years were retrospectively studied to summarize the features and trends of thyroid cancer in patients with thyroidectomies in Beijing, China.
- The clinical practice was reviewed over this long period of time to evaluate the performance of the preoperative diagnosis and risk stratification in a major hospital in Beijing.
- The retrospective nature of this study led to limited survival data, which should have been included to evaluate the improvement of clinical outcome during the 22-year period.

## Introduction

Thyroid nodules occur in about 4-7% of the population, and 8-16% of these contain malignant elements <sup>1</sup>. Thyroid cancer is the most common endocrine cancer <sup>1</sup>, and approximately 90% of these are differentiated, including predominantly papillary thyroid carcinoma (PTC) and, to a less extent, follicular thyroid carcinoma <sup>2</sup>. These subtypes are generally associated with a more favorable prognosis and higher cure rate <sup>3</sup>, when compared with less common but more aggressive forms of thyroid cancer, such as medullary thyroid cancer, anaplastic thyroid cancer, and thyroid sarcoma or lymphoma <sup>4</sup>.

The past few decades have witnessed an increase in the incidence of thyroid cancer, while the associated mortality remains unchanged <sup>5-9</sup>. In addition, the number of newly diagnosed thyroid cancer cases with smaller tumors increased. Between 2008 and 2009, 39% of thyroid cancer patients were diagnosed with tumors smaller than 1 cm, when compared to 25% of patients diagnosed between 1988 and 1989 <sup>10</sup>. This was due to the proactive screening of thyroid cancer, particularly through the application of sensitive surveillance modalities in recent years <sup>11-15</sup>. Advanced imaging techniques, such as ultrasonography, computational tomography, magnetic resonance imaging and positron emission tomography, along with fine-needle aspiration biopsy have dramatically improved the detection of small thyroid nodules, and facilitated the early diagnosis of thyroid cancer <sup>16-18</sup>.

However, the increased incidence of thyroid cancer has also been considered to be associated with over-diagnosis <sup>18-22</sup> and environmental factors <sup>6 23</sup>. The screening of highly prevalent thyroid nodules for those with malignant potential remains challenging, although a number of guidelines have recently been proposed for the diagnosis and management of thyroid nodules <sup>24</sup>. Identifying nodules with high risk of malignancy during thyroidectomy represents a cost-effective approach <sup>25 26</sup>. Therefore, in this study, the features and trends of thyroid cancer

1  
2  
3 in patients with thyroidectomies in China were retrospectively analyzed to examine whether  
4 the decrease in diagnosable size of thyroid nodules is associated with misdiagnosis, providing  
5 further insight into its diagnosis and management.  
6  
7  
8  
9  
10  
11  
12

### 13 **Materials and Methods**

14  
15  
16 This study was approved by the Chinese People's Liberation Army (PLA) General  
17 Hospital Ethics Committee, and written informed consents obtained from all patients for  
18 retrospective studies.  
19  
20  
21  
22  
23  
24  
25  
26

#### 27 ***Data collection***

28  
29  
30 The clinical database for patients undergoing thyroidectomies from 1994 to 2015 at the  
31 Department of General Surgery of PLA General Hospital (Beijing, China) was revisited, and  
32 the thyroid pathology reports were screened and reviewed to analyze the correlation of the size  
33 of thyroid nodules with other pathological features.  
34  
35  
36  
37  
38  
39

40 The clinical parameters used in the analysis included front neck discomfort or pain,  
41 dysphagia, dysphonia or hoarseness, dyspnea, sign of thyroid nodule and thyroid gland  
42 enlargement, as well as ultrasound features. These data were individually checked, and cases  
43 with inconsistent data were excluded before the statistical analysis. As a result, 10,798 eligible  
44 cases with thyroidectomies from 1994 to 2015 were recruited.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

#### 55 ***Data analysis and statistics***

56  
57  
58 Benign or malignant thyroid nodules were diagnosed based on pathological features, and  
59  
60

1  
2  
3 malignant nodules were reported as papillary (PTC), follicular (FTC), medullary (MTC), or  
4  
5 anaplastic thyroid carcinoma (ATC). Papillary thyroid carcinomas were further sub-classified  
6  
7 into clinically relevant PTCs (crPTCs) >10 mm in diameter and micro-PTCs (mPTCs) ≤10 mm  
8  
9 in diameter (the largest diameter of a nodule). These sub-groups were compared, when  
10  
11 appropriate, in the analysis.  
12  
13

14  
15 Patients were treated by surgery, often with lymph node dissection, depending on the  
16  
17 clinical features and the number, location and size of the involved lymph node, which was  
18  
19 assessed by pre-operative imaging analysis and intraoperative frozen section pathological  
20  
21 analysis. Tumors within 10 mm in size and had no involvement of lymph nodes were resected  
22  
23 without the removal of lymph nodes. When the pre-operative imaging revealed no  
24  
25 abnormalities in the lymph nodes, but malignancy was confirmed by intraoperative frozen  
26  
27 section analysis, ipsilateral central neck node dissection was performed. If the preoperative  
28  
29 sonography or intraoperative examination revealed abnormal lymph nodes, and frozen section  
30  
31 analysis confirmed the malignancy, improved lateral neck lymph node dissection was  
32  
33 performed.  
34  
35  
36  
37  
38

39 Statistical analysis was performed using the Statistical Package for the Social Sciences  
40  
41 (SPSS, Version 17.0; IBM, Armonk, NY). Data were presented as mean ± standard deviation  
42  
43 or mean ± standard error, when appropriate. Chi-square test was used to compare different  
44  
45 categories and generate the trend lines. Furthermore, *t*-test was used for comparisons between  
46  
47 groups, and logistic regression was performed to calculate the risk factors for lymph node  
48  
49 metastasis (LNM). The data analysis was adjusted for confounders, such as age, gender, nodule  
50  
51 size and the presence of Hashimoto thyroiditis. A two-tailed  $P < 0.05$  was considered  
52  
53 statistically significant.  
54  
55  
56  
57  
58  
59  
60

### ***Patient and public involvement***

This retrospective study did not involve patients or the public in the development of research initiatives and outcome measures, as well as the design and implementation of the study. The study covered a period of 22 years, which ranged between 1994 and 2015. Therefore, there was no possibility or plan to disseminate the results among the participants.

## **Results**

### ***Malignancy rate increased from 1994 to 2015***

The numbers of benign and malignant cases of thyroid cancer detected during thyroidectomy from 1994 to 2015 are summarized in Table 1. As the number of thyroidectomy surgeries increased due to the improved diagnosis of thyroid cancer, the number of benign and malignant cases gradually increased. Noticeably, the malignancy rate of thyroid nodules dramatically increased from 16.8% during the biennial period of 1994-1995 to 69.8% during the period of 2014-2015 ( $P<0.05$ ), while the benign rate decreased from 83.2% to 30.2% ( $P<0.05$ ).

### ***The diagnosis rate of PTC increased from 1994 to 2015***

Among the 10,798 cases recruited, 5,235 cases were found to be malignant (Table 2). Furthermore, a majority of patients (63.6%) were found with multiple cancers. Moreover, 48.1% of patients had unilateral cancer, and the remaining 51.9% of patients had bilateral cancer (Table 2). In addition, most of the malignant cases were recorded as PTCs, which exhibited a significant increase from 65.3% during the period of 1994-1995 to 98.2% during the period of

1  
2  
3 2014-2015 ( $P < 0.05$ , Figure 1), while the diagnosis rates of other histotypes concurrently  
4  
5 decreased (Table 2 and Figure 1).  
6  
7  
8  
9

### 10 11 ***Detection size of thyroid nodules decreased from 1994 to 2015*** 12

13  
14 The review of the clinicopathological information of malignant cases suggested that most  
15 of these patients were free of clinically relevant symptoms and physical signs (Figures 2A and  
16 2B), and only 9% of patients exhibited different degrees of discomfort, such as pain and  
17 dysphagia. The enlargement of thyroid glands were often noticed, but not necessarily by health  
18 professionals, during routine physical examination. However, 34% of tumors were impalpable,  
19 which was likely due to the depth of the intra-thyroidal microcarcinoma. By ultrasonography,  
20 37% of patients were detected with single thyroid tumors, while the remaining patients had  
21 multiple lesions (Figure 2C).  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32  
33 From 1994 to 2015, the size of thyroid nodules has been reported to significantly decrease,  
34 with the mean diameter reduced from  $2.6 \pm 1.4$  cm to  $1.2 \pm 0.9$  cm (Figure 2D). This trend  
35 roughly correlates with the increase in the rate of preoperative fine needle aspiration (FNA),  
36 which ranged from 15% in 2004 to 74% in 2013, although this rate regressed to 57% between  
37 2014 and 2015 (Figure 2E). In addition, during the same period, the total thyroidectomy rate  
38 remained unchanged from 1994 to 2007, but gradually increased from 2008 to 2013, and  
39 decreased sharply to 3% from 2014 to 2015 (Figure 2F).  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

### 52 53 ***The size of the thyroid cancer at diagnosis and metastasis rate decreased from 1994 to 2015*** 54

55  
56 Considering the high prevalence of PTCs, 4,980 cases were compared to 255 cases of other  
57 subtypes all-together, and further data analysis was restricted to this type of thyroid cancer. As  
58  
59  
60

1  
2  
3 shown in Table 3, the mean age of patients at diagnosis was  $43.7 \pm 11.3$  years old, with no  
4 significant variation from 1994 to 2015. Furthermore, the incidence of PTC was considerably  
5 higher in women than in men, in which approximately two thirds of these patients were female.  
6  
7 It is noteworthy that the average diameter of PTCs at diagnosis decreased from  $2.3 \pm 1.1$  cm in  
8 1994 to  $1.2 \pm 0.9$  cm in 2015 ( $P < 0.05$ , Table 3). Correlating with this trend was the increase  
9 in the percentage of mPTCs from 13.3% between 1994 and 1995 to 51.2% between 2010 and  
10 2011 ( $P < 0.05$ , Table 3). This likely resulted from a more meticulous pathological examination.  
11  
12 Interestingly, the detection rate of mPTCs decreased to 26.5 between 2014 and 2015.  
13  
14  
15  
16  
17  
18  
19  
20  
21

22 Among the PTC cases studied, 1,212 patients were found with LNM, but its occurrence  
23 significantly decreased with the reduction in tumor size ( $P < 0.05$ , Table 3). This was associated  
24 with the increased diagnosis rate of mPTCs, which shows an apparently lower LNM potential  
25 in comparison with crPTCs (Table 4). Before 2007, the difference between the LNM rates of  
26 mPTC and crPTC were appreciable, but this not statistically significant most of time due to the  
27 limited size of the cohort. With the increase in PTC diagnosis after 2008, a significantly lower  
28 LNM occurrence was found for mPTCs, when compared to crPTCs (Table 4).  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

### 42 ***Determinant factors of local lymph node metastasis in PTC, mPTC and crPTC***

43  
44  
45 To identify the risk factors for local LNM in PTC, mPTC and crPTC, a logistic regression  
46 analysis was performed. The results support the correlation of LNM with nodules  $> 1$  cm (odd  
47 ratio [OR]: 2.480, confidence interval [CI]: 0.428 – 0.613;  $P < 0.001$ ) and male gender (OR:  
48 1.627, CI: 1.376-1.923;  $P < 0.001$ ), and its inverse correlation with the age of  $\geq 45$  years old  
49 (OR: 0.512, CI: 2.040-2.902;  $P < 0.001$ ) after adjustment for other covariates in all PTCs (Figure  
50 3A, Table 2). Hashimoto's thyroiditis presented no risk for LNM (Figure 3A). Consistent data  
51 were also obtained from patients with mPTC and crPTC (Figures 3B and 3C; Tables 3 and 4).  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

Thyroid cancer is diagnosed in nearly 300,000 people annually all over the world <sup>27</sup>. Although these malignancies are mostly differentiated and generally associated with a good prognosis, the involvement of local lymph nodes is frequently observed. Proactive screening for malignancies from a substantial population of thyroid nodes and accurate histopathological stratification are crucial for the clinical decision and improvement of patient outcome. The present study reviewed 10,798 cases of thyroidectomy undertaken in a major hospital located in one of the most populated city in the world for a period of over 22 years, summarized the clinical features of 5,235 cases of thyroid cancer, and analyzed the trend of PTCs and risk factors for predicting LNM. Among these patients, about 20% were from Beijing, while the rest 80% were from other regions in China where the disease could not be diagnosed definitely in local hospitals. Therefore, our patient cohort generally represented all China even though bias towards the difficult cases might exist.

The present analysis unveiled a gradual but significant increase in thyroid malignancy detection rate between the period of 1994 and 2015, which ranged from 16.8% to 69.8%. These percentages are generally within the wide-range detection rate (6.7-56%) of thyroid cancer worldwide <sup>25 28 29</sup>, although data between 2014 and 2015 was relatively higher than earlier periods. Furthermore, the detection rates varied across different centers, which were likely caused by the different guidelines and algorithms followed by physicians and surgeons. The increase in detection rate from 1994 to 2015 reflects the improvement in diagnosis, through the advances in imaging technology and the increasing use of FNA, together with the shift of routine node dissection towards therapeutic dissection in the treatment. In addition, the appropriate preoperative risk stratification of thyroid nodules, which was a result of improved



1  
2  
3 clinical evaluation, thyroid function test, ultrasonography and molecular diagnosis in recent  
4 years, has diverted a lot of patients from thyroidectomy, contributing to the increased diagnosis  
5 of thyroid cancer. These data support published guidelines<sup>30 31</sup> and highlights the importance  
6 of combining imaging, FNA, cytology and molecular diagnosis. However, the contribution of  
7 social and environmental stresses could not be rule out, which is beyond the scope of the  
8 present retrospective study. It is noteworthy that the present study covered a period during  
9 which China was undergoing the largest scale of industrialization in modern history. This  
10 inevitably led to dramatic social and environmental changes.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

22 Papillary carcinoma accounts for 95.1% of malignancies in the whole cohort, and reached  
23 as high as 98.2% among patients diagnosed between 2014 and 2015. These rates were  
24 comparable to the findings of another study performed in Nanjing, China<sup>25</sup>, but were higher  
25 than those in other reports<sup>32</sup>, which was likely due to the increase in PTCs, as previously  
26 suggested<sup>33</sup>. The high detection rate for PTC was attributable to the increasing use of head  
27 and neck imaging, which detects sub-palpable (yet potentially malignant) thyroid nodules, and  
28 ultrasound-guided FNA, which improves the preoperative detection of malignancy. With the  
29 use of neck ultrasonography and other diagnostic approaches, the average size of PTCs at  
30 diagnosis has significantly reduced from  $2.3 \pm 1.1$  cm in 1994 to  $1.2 \pm 0.9$  cm in 2015, and this  
31 was similar to the trends reported in previous studies<sup>10 25</sup>. This progress allows for the early  
32 detection of thyroid cancer, which leads to the increasing trend of hemithyroidectomy, when  
33 compared to total thyroidectomy, and the intensified follow-up of thyroid cancer patients in  
34 recent years in our practice following the American Thyroid Association (ATA) guidelines<sup>30</sup>  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 thyroid nodules and a more judicious use of thyroid cancer treatment, in order to minimize risk  
4  
5 and maximize benefits to patients<sup>33</sup>.  
6  
7

8 The present data suggests that nodules >1 cm and the male gender predict a high risk of  
9  
10 LNM, while the age of  $\geq 45$  years old is associated with low LNM potentials, and this is  
11  
12 consistent with a previous finding<sup>25</sup>. Therefore, more attention is needed for these patients in  
13  
14 future practice. However, in this single-center study, factors taken into account for the logistic  
15  
16 regression analysis were limited due to the retrospective nature of the study. Future studies are  
17  
18 needed to characterize the association of other clinical and biochemical parameters with thyroid  
19  
20 cancer metastasis and patient outcome. Characterizing the contribution of social and  
21  
22 environmental stresses to the occurrence of thyroid cancer would also be of significant social  
23  
24 economical value.  
25  
26  
27  
28  
29

30 In the present study, the clinical data of 10,798 patients treated by thyroidectomy was  
31  
32 retrospectively analyzed to determine the features and trends of thyroid cancer in the past 22  
33  
34 years. The present data suggested a significant increase in the detection rate of thyroid cancer,  
35  
36 particularly mPTC, which has become the dominant form of thyroid cancer. As a result, the  
37  
38 occurrence of LNM has been decreasing with time. The present results suggest the adequacy  
39  
40 of present preoperative diagnosis and risk stratification, although overdiagnosis and  
41  
42 overtreatment require future attention of physicians and surgeons in view of the rapid increase  
43  
44 in the number of thyroidectomies.  
45  
46  
47  
48  
49  
50

## 51 **Acknowledgements**

52  
53  
54 We gratefully acknowledge the invaluable contribution of the doctors and nurses of  
55  
56 Chinese PLA General Hospital and the patients involved in this study.  
57  
58  
59  
60

## **Funding**

This study was supported by a grant from the Medical Science and Technology Foundation of the Military “Twelve-Five” Program (CWS11J063) to ZHL

## **Authors' contributions**

ZL designed the study, collected and analyzed data, and wrote the manuscript. PP contributed in writing the manuscript. ZL, LYK, WFL, YGQ, DJ and WXL assisted with the data presentation and manuscript writing. LZH, DJT and MYM contributed in the study design, data analysis and manuscript writing. All authors read and approved the final manuscript.

## **Competing interests**

The authors have no conflicts of interest to disclose.

## **Data sharing statement**

Data will be available upon request to the corresponding author

## References

1. Burman KD, Wartofsky L. CLINICAL PRACTICE. Thyroid Nodules. *N Engl J Med* 2015;373:2347-56.
2. Ron E, Schneider AB. Thyroid Cancer In: Schottenfeld D, Jr. FJF, eds. *Cancer Epidemiology and Prevention* New York: Oxford University Press, 2006:975-94.
3. Schlumberger MJ. Papillary and follicular thyroid carcinoma. *N Engl J Med* 1998;338:297-306.
4. Spielman DB, Badhey A, Kadakia S, et al. Rare Thyroid Malignancies: an Overview for the Oncologist. *Clin Oncol (R Coll Radiol)* 2017;29:298-306.
5. Brito JP, Kim HJ, Han SJ, et al. Geographic Distribution and Evolution of Thyroid Cancer Epidemic in South Korea. *Thyroid* 2016;26:864-5.
6. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. *Cancer Epidemiol Biomarkers Prev* 2009;18:784-91.
7. Pandeya N, McLeod DS, Balasubramaniam K, et al. Increasing thyroid cancer incidence in Queensland, Australia 1982-2008 - true increase or overdiagnosis? *Clin Endocrinol (Oxf)* 2015.
8. Uhry Z, Colonna M, Remontet L, et al. Estimating infra-national and national thyroid cancer incidence in France from cancer registries data and national hospital discharge database. *Eur J Epidemiol* 2007;22:607-14.
9. Wang Y, Wang W. Increasing incidence of thyroid cancer in Shanghai, China, 1983-2007. *Asia Pac J Public Health* 2015;27:NP223-9.

10. Davies L, Welch HG. Current thyroid cancer trends in the United States. *JAMA Otolaryngol Head Neck Surg* 2014;140:317-22.
11. Brito JP, Gionfriddo M, Morris JC, et al. Overdiagnosis of thyroid cancer and graves' disease. *Thyroid* 2014;24:402-3.
12. Brito JP, Hay ID, Morris JC. Low risk papillary thyroid cancer. *BMJ* 2014;348:g3045.
13. Brito JP, Morris JC, Montori VM. Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. *BMJ* 2013;347:f4706.
14. Kilfoy BA, Zheng T, Holford TR, et al. International patterns and trends in thyroid cancer incidence, 1973-2002. *Cancer Causes Control* 2009;20:525-31.
15. Trimboli P, Guglielmi R, Monti S, et al. Ultrasound sensitivity for thyroid malignancy is increased by real-time elastography: a prospective multicenter study. *J Clin Endocrinol Metab* 2012;97:4524-30.
16. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. *JAMA* 2006;295:2164-7.
17. Kent WD, Hall SF, Isotalo PA, et al. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. *CMAJ* 2007;177:1357-61.
18. Sosa JA, Hanna JW, Robinson KA, et al. Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States. *Surgery* 2013;154:1420-6; discussion 6-7.
19. Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic"--screening and overdiagnosis. *N Engl J Med* 2014;371:1765-7.
20. Brito JP, Davies L. Is there really an increased incidence of thyroid cancer? *Curr Opin*

- 1  
2  
3 Endocrinol Diabetes Obes 2014;21:405-8.  
4  
5  
6 21. Franceschi S, Vaccarella S. Thyroid cancer: an epidemic of disease or an epidemic of  
7  
8 diagnosis? *Int J Cancer* 2015;136:2738-9.  
9  
10  
11 22. Morris LG, Tuttle RM, Davies L. Changing Trends in the Incidence of Thyroid Cancer in  
12  
13 the United States. *JAMA Otolaryngol Head Neck Surg* 2016;142:709-11.  
14  
15  
16 23. Aschebrook-Kilfoy B, Grogan RH. Re: Brito et al., overdiagnosis of thyroid cancer and  
17  
18 Graves' disease. *Thyroid* 2014;24:403-4.  
19  
20  
21  
22 24. Paschke R, Hegedus L, Alexander E, et al. Thyroid nodule guidelines: agreement,  
23  
24 disagreement and need for future research. *Nat Rev Endocrinol* 2011;7:354-61.  
25  
26  
27 25. Liu X, Zhu L, Wang Z, et al. Evolutionary features of thyroid cancer in patients with  
28  
29 thyroidectomies from 2008 to 2013 in China. *Sci Rep* 2016;6:28414.  
30  
31  
32 26. Liu XY, Zhu LJ, Cui D, et al. Annual financial impact of thyroidectomies for nodular  
33  
34 thyroid disease in China. *Asian Pac J Cancer Prev* 2014;15:5921-6.  
35  
36  
37 27. La Vecchia C, Malvezzi M, Bosetti C, et al. Thyroid cancer mortality and incidence: a  
38  
39 global overview. *Int J Cancer* 2015;136:2187-95.  
40  
41  
42  
43 28. Wienhold R, Scholz M, Adler JR, et al. The management of thyroid nodules: a retrospective  
44  
45 analysis of health insurance data. *Dtsch Arztebl Int* 2013;110:827-34.  
46  
47  
48 29. Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary approach  
49  
50 to thyroid nodule diagnostic evaluation. *Cancer* 2007;111:508-16.  
51  
52  
53 30. American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated Thyroid  
54  
55 C, Cooper DS, et al. Revised American Thyroid Association management guidelines  
56  
57 for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid*  
58  
59  
60

1  
2  
3 2009;19:1167-214.  
4  
5

- 6 31. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with  
7 thyroid nodules and differentiated thyroid cancer. *Thyroid* 2006;16:109-42.  
8  
9  
10  
11 32. Othman NH, Omar E, Naing NN. Spectrum of thyroid lesions in hospital Universiti Sains  
12 Malaysia over 11 years and a review of thyroid cancers in Malaysia. *Asian Pac J Cancer*  
13 *Prev* 2009;10:87-90.  
14  
15  
16  
17  
18 33. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association  
19 Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated  
20 Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid  
21 Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid  
22 Nodules and Differentiated Thyroid Cancer. *Thyroid* 2016;26:1-133.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1. Detection rate of malignancy among patients undergoing thyroidectomy from 1994 to 2015**

<sup>a</sup> The last 2 digits of the years are displayed (hereafter); <sup>b</sup> Percentages significantly different from the previous year; <sup>c</sup> Percentages significantly different

Period	94-95 <sup>a</sup>	96-97	98-99	00-01	02-03	04-05	06-07	08-09	10-11	12-13	14-15	Total	<i>P</i>
Benign, <i>n</i>	114	136	169	268	286	495	535	738	901	1033	890	5563	<0.001
(%)	(83.2)	(86.1) <sup>b,c</sup>	(88.0) <sup>b,c</sup>	(83.0) <sup>b</sup>	(80.1) <sup>b,c</sup>	(79.2) <sup>c</sup>	(71.4) <sup>b,c</sup>	(64.6) <sup>b,c</sup>	(52.4) <sup>b,c</sup>	(42.2) <sup>b,c</sup>	(30.2) <sup>b,c</sup>	(51.5)	
Cancer, <i>n</i>	23	22	23	55	71	130	214	405	817	1413	2060	5235	
(%)	(16.8)	(13.9) <sup>a,b</sup>	(12.0) <sup>a,b</sup>	(17.0) <sup>a</sup>	(19.9) <sup>a,b</sup>	(20.8) <sup>b</sup>	(28.6) <sup>a,b</sup>	(35.4) <sup>a,b</sup>	(47.6) <sup>a,b</sup>	(57.8) <sup>a,b</sup>	(69.8) <sup>a,b</sup>	(48.5)	
Total	137	158	192	323	357	625	749	1143	1718	2446	2950	10798	

within the period of 94-95.



**Table 2. Pathological classification of all thyroid malignancies from 1994 to 2015**

Period	94-95	96-97	98-99	00-01	02-03	04-05	06-07	08-09	10-11	12-13	14-15	<i>P</i> for difference	<i>P</i> for trend
PTC, <i>n</i> (%)	15 (65.3)	17 (77.3)	17 (73.9)	39 (70.9)	50 (70.4)	107 (82.3)	185 (86.4)	383 (94.6)	768 (94.0)	1376 (97.4)	2023 (98.2)	<0.001	<0.001
FTC, <i>n</i> (%)	3 (13.0)	1 (4.5)	4 (17.3)	10 (18.1)	9 (12.7)	17 (13.1)	18 (8.4)	9 (2.2)	25 (3.0)	17 (1.2)	20 (0.9)	<0.001	<0.001
MTC, <i>n</i> (%)	1 (4.3)	2 (9.1)	1 (4.3)	4 (7.3)	2 (2.8)	1 (0.8)	2 (0.9)	5 (1.2)	14 (1.7)	12 (0.8)	12 (0.6)	<0.001	<0.001
ATC, <i>n</i> (%)	0 (0)	0 (0)	1 (4.3)	1 (1.8)	3 (4.2)	1 (0.8)	1 (0.5)	2 (0.5)	1 (0.1)	1 (0.1)	2 (0.1)	<0.001	<0.001
Other, <i>n</i> (%)	4 (17.4)	2 (9.1)	0 (0)	1 (1.8)	7 (9.9)	4 (3.1)	7 (3.3)	6 (1.5)	9 (1.1)	7 (0.5)	3 (0.1)	<0.001	<0.001
Unilateral	14 (60.9)	14 (63.6)	13 (56.5)	31 (56.4)	38 (53.5)	72 (55.4)	122 (57.0)	213 (52.6)	389 (47.6)	616 (43.6)	991 (48.1)	0.071	<0.001
Bilateral	9 (39.1)	8 (36.4)	10 (43.5)	24 (43.6)	33 (46.5)	58 (44.6)	92 (43.0)	192 (47.4)	428 (52.4)	797 (56.4)	1069 (51.9)		
Solitary	7 (30.4)	13 (59.1)	11 (47.8)	27 (49.1)	28 (39.4)	59 (45.4)	105 (49.0)	172 (42.5)	292 (35.7)	456 (32.3)	749 (36.4)	<0.001	<0.001
Multiple	16 (69.6)	9 (40.9)	12 (52.2)	28 (50.9)	43 (60.6)	71 (54.6)	109 (51.0)	233 (57.5)	525 (64.3)	957 (67.7)	1311 (63.6)		

1  
2 All cancer, *n* 23 22 23 55 71 130 214 405 817 1413 2060  
3  
4

5 

---

PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; MTC, medullary thyroid carcinoma; ATC, anaplastic thyroid carcinoma; other  
6  
7 histotypes of carcinoma collectively refer to cancer other than PTC, FTC, MTC and ATC, including poorly differentiated thyroid cancer, squamous cell  
8  
9 carcinomas, B cell lymphomas of thyroid, spindle cell carcinoma, adenoid cystic carcinoma, renal clear cell metastasis and Langerhans cell histocytosis  
10  
11 of the thyroid gland.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

**Table 3. Clinicopathological features of PTCs from 1994 to 2015**

Period	94-95	96-97	98-99	00-01	02-03	04-05	06-07	08-09	10-11	12-13	14-15	Total	<i>P</i> for difference	<i>P</i> for trend
Age, year	46.9±14.3	43.1±10.7	41.1±12.9	44.9±14.8	44.6±14.5	43.8±12.4	44.6±12.4	42.7±12.4	43.9±11.2	43.9±11.1	43.6±10.9	43.7±11.3	0.643	
Male, <i>n</i>	5	3	6	11	18	34	60	115	227	366	616	1461	0.434	0.664
(%)	(33.3)	(17.6)	(35.3)	(28.2)	(36)	(31.8)	(32.4)	(30.0)	(29.6)	(26.6)	(30.4)	(29.3)		
Female, <i>n</i>	10	14	11	28	32	73	125	268	541	1010	1407	3519		
(%)	(66.7)	(82.4) <sup>ab</sup>	(64.7.0) <sup>a</sup>	(71.8) <sup>a</sup>	(64) <sup>a,b</sup>	(68.2) <sup>b</sup>	(67.6) <sup>a,b</sup>	(70.0) <sup>a,b</sup>	(70.4) <sup>a,b</sup>	(73.4) <sup>a</sup>	(69.6) <sup>a</sup>	(70.7)		
Size <sup>c</sup> , cm	2.3±1.1	2.6±1.9	2.1±1.3	2.2±1.6	2.2±1.4	2.2±1.6	1.7±1.1 <sup>ab</sup>	1.5±1.0 <sup>b</sup>	1.3±0.9 <sup>ab</sup>	1.2±0.8 <sup>ab</sup>	1.2±0.9 <sup>b</sup>	1.4±1.0	<0.001	
CrPTC, <i>n</i>	13	15	12	32	41	87	118	238	375	696	1486	3113	<0.001	0.213
(%)	(86.7)	(88.2)	(70.6)	(82.1)	(82.0)	(81.3)	(63.8) <sup>a</sup>	(62.1) <sup>b</sup>	(48.8) <sup>ab</sup>	(50.6) <sup>b</sup>	(73.5) <sup>a</sup>	(62.5)		
mPTC, <i>n</i>	2	2	5	7	9	20	67	145	393	680	537	1866		
(%)	(13.3)	(11.8)	(29.4)	(17.9)	(18.0)	(18.7)	(36.2)	(37.9)	(51.2)	(49.4)	(26.5)	(37.5)		

1															
2	LNM, <i>n</i>	5	5	7	22	17	27	55	96	192	372	414	1212	<0.001	<0.001
3															
4	(%)	(33.3)	(29.4)	(41.2)	(56.4)	(34)	(25.2)	(29.7)	(25.1)	(25.0)	(27.0)	(20.5) <sup>a</sup>	(24.3)		
5															
6															
7	No-LNM, <i>n</i>	10	12	10	17	33	80	130	287	576	1004	1609	3768		
8															
9															
10	(%)	(66.7)	(70.6)	(58.8)	(43.6)	(66)	(74.8)	(70.3)	(74.9)	(75.0)	(73.0)	(79.5)	(75.7)		
11															
12															
13	Total	15	17	17	39	50	107	185	383	768	1376	2023		<0.001	<0.001
14															
15															

<sup>a</sup> Percentages significantly different from the previous year; <sup>b</sup> Percentages significantly different within the period of 08-09; <sup>c</sup> Mean diameter; crPTC, clinical relevant papillary thyroid carcinoma; mPTC, micro papillary thyroid carcinoma; LNM, lymph node metastasis; LN, lymph node.

**Table 4. Rate of local lymph node metastasis in patients with crPTC and mPTC from 2008 to 2013**

	94-95	96-97	98-99	00-01	02-03	04-05	06-07	08-09	10-11	12-13	14-15	Total	<i>P</i> for difference	<i>P</i> for trend
crPTC, <i>n</i> (%)	3(23.1)	5(33.3)	6(50.0)	19(59.4)	17(41.5)	24(27.6)	35(29.7)	73(30.7)	130(34.7)	243(34.9)	330(22.2)	885(28.4)	<0.001	<0.001
mPTC, <i>n</i> (%)	2(100)	0(0)	1(20.0)	3(42.9)	0(0)	3(15.0)	20(29.9)	23(16.0)	62(15.8)	129(19.0)	84(15.6)	327(17.5)	0.005	0.087
<i>P</i> -value	0.032	0.331	0.252	0.425	0.017	0.243	0.978	0.001	0.000	0.000	0.001			

crPTC, clinical relevant papillary thyroid carcinoma; mPTC, micro papillary thyroid carcinoma.

## Figure legends

**Figure 1** Trends in the diagnosis of various subtype thyroid malignancies, presented as permillage (rate per thousand) of thyroid cancer, from 1994 to 2015.

**Figure 2** Clinical, surgical and ultrasound features during the evolvement of thyroidectomy and the diagnosis of thyroid cancer from 1994 to 2015. Data on the symptoms (A), physical signs (B), nodule multiplicity (C), ultrasonographic sizes of nodules (D), FNA ratio (E), and thyroidectomy types (F) were summarized.

**Figure 3** Determinant factors of the lymph node metastasis of PTC (A), mPTC (B) and crPTC (C). Logistic regression was performed to define factors associated with local lymph node metastasis.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1

98x108mm (600 x 600 DPI)




Figure 2 (Revised)

211x262mm (300 x 300 DPI)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60






Figure 3

170x313mm (300 x 300 DPI)

## STROBE (Strengthening The Reporting of OBServational Studies in Epidemiology) Checklist

A checklist of items that should be included in reports of observational studies. You must report the page number in your manuscript where you consider each of the items listed in this checklist. If you have not included this information, either revise your manuscript accordingly before submitting or note N/A.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

Section and Item	Item No.	Recommendation	Reported on Page No.
Title and Abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1&2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/Rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
<b>Methods</b>			
Study Design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5&6
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	NA
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	NA
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	NA
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5&6

Section and Item	Item No.	Recommendation	Reported on Page No.
Data Sources/ Measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5&6
Bias	9	Describe any efforts to address potential sources of bias	NA
Study Size	10	Explain how the study size was arrived at	
Quantitative Variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5&6
Statistical Methods	12	(a) Describe all statistical methods, including those used to control for confounding	5&6
		(b) Describe any methods used to examine subgroups and interactions	5&6
		(c) Explain how missing data were addressed	5&6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	NA
		(e) Describe any sensitivity analyses	NA
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive Data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	NA
Outcome Data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	7-9
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	NA
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	NA

Section and Item	Item No.	Recommendation	Reported on Page No.
Main Results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-9
		(b) Report category boundaries when continuous variables were categorized	7-9
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other Analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
<b>Discussion</b>			
Key Results	18	Summarise key results with reference to study objectives	9-10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10-11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-11
Generalisability	21	Discuss the generalisability (external validity) of the study results	NA
<b>Other Information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Once you have completed this checklist, please save a copy and upload it as part of your submission. DO NOT include this checklist as part of the main manuscript document. It must be uploaded as a separate file.**